<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD05870000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P00734</UniProt_ID>
  <Seq_Length>622</Seq_Length>
  <Molecule_Weight>70037</Molecule_Weight>
  <KEGG_ID>hsa:2147</KEGG_ID>
  <Orthology_ID>K01313</Orthology_ID>
  <EBI_ID>EBI-297094</EBI_ID>
  <Function_Summary>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.</Function_Summary>
  <Catalytic_Mechanism>Selective cleavage of Arg-|-Gly bonds in fibrinogen to form fibrin and release fibrinopeptides A and B.</Catalytic_Mechanism>
  <Pfam_ID>PF00594:Gla@@PF00051:Kringle@@PF09396:Thrombin_light@@PF00089:Trypsin</Pfam_ID>
  <Allosteric_Activator_Count>1</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>48</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>2</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Activation peptide fragment 2</Alias>
      <Alias>Thrombin light chain</Alias>
      <Alias>Coagulation factor II</Alias>
      <Alias>Thrombin heavy chain</Alias>
      <Alias>Activation peptide fragment 1</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type endopeptidase activity</Keyword>
      <Ontology_ID>GO:0004252</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.</Detail>
      <Keyword>Peptidase activity</Keyword>
      <Ontology_ID>GO:0008233</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type peptidase activity</Keyword>
      <Ontology_ID>GO:0008236</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with thrombospondin to initiate a change in cell activity.</Detail>
      <Keyword>Thrombospondin receptor activity</Keyword>
      <Ontology_ID>GO:0070053</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with calcium ions (Ca2+).</Detail>
      <Keyword>Calcium ion binding</Keyword>
      <Ontology_ID>GO:0005509</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>The function that stimulates a cell to grow or proliferate. Most growth factors have other actions besides the induction of cell growth or proliferation.</Detail>
      <Keyword>Growth factor activity</Keyword>
      <Ontology_ID>GO:0008083</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>72</Position>
      <Original>Glu</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>165</Position>
      <Original>Thr</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>461</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>509</Position>
      <Original>Glu</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>425</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>431</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>601</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>314</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>380</Position>
      <Original>Met</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>314</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>386</Position>
      <Original>Pro</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>200</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the release into the cytosolic compartment of calcium ions sequestered in the endoplasmic reticulum or mitochondria.</Detail>
      <Keyword>Positive regulation of release of sequestered calcium ion into cytosol</Keyword>
      <Ontology_ID>GO:0051281</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>An ongoing process that solubilizes fibrin, chiefly by the proteolytic action of plasmin, resulting in the removal of small blood clots.</Detail>
      <Keyword>Fibrinolysis</Keyword>
      <Ontology_ID>GO:0042730</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals initiated by the binding of an extracellular ligand to a receptor on the surface of the target cell.</Detail>
      <Keyword>Cell surface receptor linked signaling pathway</Keyword>
      <Ontology_ID>GO:0007166</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>An acute inflammatory response that involves non-antibody proteins whose concentrations in the plasma increase in response to infection or injury of homeothermic animals.</Detail>
      <Keyword>Acute-phase response</Keyword>
      <Ontology_ID>GO:0006953</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals.</Detail>
      <Keyword>Positive regulation of collagen biosynthetic process</Keyword>
      <Ontology_ID>GO:0032967</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.</Detail>
      <Keyword>Platelet activation</Keyword>
      <Ontology_ID>GO:0030168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The covalent alteration of one or more amino acids occurring in a protein after the protein has been completely translated and released from the ribosome.</Detail>
      <Keyword>Post-translational protein modification</Keyword>
      <Ontology_ID>GO:0043687</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate or frequency of platelet activation. Platelet activation is a series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue.</Detail>
      <Keyword>Negative regulation of platelet activation</Keyword>
      <Ontology_ID>GO:0010544</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of reactive oxygen species metabolic process.</Detail>
      <Keyword>Positive regulation of reactive oxygen species metabolic process</Keyword>
      <Ontology_ID>GO:2000379</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of calcium ions within the cytosol of a cell or between the cytosol and its surroundings.</Detail>
      <Keyword>Cytosolic calcium ion homeostasis</Keyword>
      <Ontology_ID>GO:0051480</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The gamma-carboxylation of peptidyl-glutamic acid; catalyzed by the vitamin K dependent gamma-glutamyl carboxylase.</Detail>
      <Keyword>Peptidyl-glutamic acid carboxylation</Keyword>
      <Ontology_ID>GO:0017187</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The movement of a leukocyte within or between different tissues and organs of the body.</Detail>
      <Keyword>Leukocyte migration</Keyword>
      <Ontology_ID>GO:0050900</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein.</Detail>
      <Keyword>Negative regulation of proteolysis</Keyword>
      <Ontology_ID>GO:0045861</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A protein activation cascade that contributes to blood coagulation and consists of the interactions among high molecular weight kininogen, prekallikrein, and factor XII that lead to the activation of clotting factor X.</Detail>
      <Keyword>Blood coagulation, intrinsic pathway</Keyword>
      <Ontology_ID>GO:0007597</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.</Detail>
      <Keyword>Blood coagulation</Keyword>
      <Ontology_ID>GO:0007596</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of fibrinolysis, an ongoing process that solubilizes fibrin, resulting in the removal of small blood clots.</Detail>
      <Keyword>Negative regulation of fibrinolysis</Keyword>
      <Ontology_ID>GO:0051918</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The stopping of bleeding (loss of body fluid) or the arrest of the circulation to an organ or part.</Detail>
      <Keyword>Hemostasis</Keyword>
      <Ontology_ID>GO:0007599</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein.</Detail>
      <Keyword>Positive regulation of protein phosphorylation</Keyword>
      <Ontology_ID>GO:0001934</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.</Detail>
      <Keyword>Proteolysis</Keyword>
      <Ontology_ID>GO:0006508</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of astrocyte differentiation.</Detail>
      <Keyword>Negative regulation of astrocyte differentiation</Keyword>
      <Ontology_ID>GO:0048712</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>49</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>75</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>62</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>63</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>69</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>68</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>72</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>59</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>50</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>57</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQECSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE</Protein_Seq>
    <DNA_Seq>GTCAGGACAGACAATTCCTCAGTGACCCAGGAGCTGACACACTATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGCCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGGGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGCGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACGGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTTGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTGAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCTGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCCGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAATGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAAGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAGTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCACAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAACTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCTGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGAGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTACCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCTCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATCGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATGCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGGGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAATGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAGATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGACCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCTGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGGGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCCAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACCCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGAGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAACCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATATGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTTGGAGAGTAGGGGGCCACTCATATTCTGGGCTCCTGGAACCAATCCCGTGAAAGAATTATTTTTGTGTTTCTAAAACTATGGTTCCCAATAAAAGTGACTCTCAGCGAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Plasma</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Golgi lumen</CellLocal>
      <Ontology_ID>GO:0005796</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Soluble fraction</CellLocal>
      <Ontology_ID>GO:0005625</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endoplasmic reticulum lumen</CellLocal>
      <Ontology_ID>GO:0005788</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular space</CellLocal>
      <Ontology_ID>GO:0005615</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>F2</Gene_Name>
    <Gene_ID>2147</Gene_ID>
    <Genbank_ACCN>NM_000506</Genbank_ACCN>
    <Protein_ACCN>NP_000497</Protein_ACCN>
    <HGNC_ID>3535</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2147</Gene_URL>
    <UCSC_ID>uc001ndf.4</UCSC_ID>
    <EMBL_ID>ENSG00000180210</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P00734</Uniprot_ID>
      <Gene_Name>F2</Gene_Name>
      <EBI_ID>EBI-989571</EBI_ID>
      <PPI_EBI_URL>EBI-297094,EBI-989571</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P07204</Uniprot_ID>
      <Gene_Name>THBD</Gene_Name>
      <EBI_ID>EBI-941422</EBI_ID>
      <PPI_EBI_URL>EBI-297094,EBI-941422</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Liver Cirrhosis</Disease_Name>
      <Disease_Detail>Liver Cirrhosis</Disease_Detail>
      <Disease_DB>LVR012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/liver_cirrhosis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Xii Deficiency</Disease_Name>
      <Disease_Detail>Factor Xii Deficiency</Disease_Detail>
      <Disease_DB>FCT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_xii_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vitamin K Deficiency Hemorrhagic Disease</Disease_Name>
      <Disease_Detail>Vitamin K Deficiency Hemorrhagic Disease</Disease_Detail>
      <Disease_DB>VTM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vitamin_k_deficiency_hemorrhagic_disease?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor X Deficiency</Disease_Name>
      <Disease_Detail>Factor X Deficiency</Disease_Detail>
      <Disease_DB>FCT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_x_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fulminant Viral Hepatitis</Disease_Name>
      <Disease_Detail>Fulminant Viral Hepatitis</Disease_Detail>
      <Disease_DB>FLM003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fulminant_viral_hepatitis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatic Coma</Disease_Name>
      <Disease_Detail>Hepatic Coma</Disease_Detail>
      <Disease_DB>HPT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatic_coma?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatitis a</Disease_Name>
      <Disease_Detail>Hepatitis a</Disease_Detail>
      <Disease_DB>HPT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatitis_a?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pseudomyxoma Peritonei</Disease_Name>
      <Disease_Detail>Pseudomyxoma Peritonei</Disease_Detail>
      <Disease_DB>PSD007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pseudomyxoma_peritonei?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cryptococcosis</Disease_Name>
      <Disease_Detail>Cryptococcosis</Disease_Detail>
      <Disease_DB>CRY005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cryptococcosis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatic Tuberculosis</Disease_Name>
      <Disease_Detail>Hepatic Tuberculosis</Disease_Detail>
      <Disease_DB>HPT008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatic_tuberculosis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mthfr Gene Mutation</Disease_Name>
      <Disease_Detail>Mthfr Gene Mutation</Disease_Detail>
      <Disease_DB>MTH044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mthfr_gene_mutation?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Scabies</Disease_Name>
      <Disease_Detail>Scabies</Disease_Detail>
      <Disease_DB>SCB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/scabies?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Wound Botulism</Disease_Name>
      <Disease_Detail>Wound Botulism</Disease_Detail>
      <Disease_DB>WND001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/wound_botulism?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemoglobin E Disease</Disease_Name>
      <Disease_Detail>Hemoglobin E Disease</Disease_Detail>
      <Disease_DB>HMG003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemoglobin_e_disease?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypoglycemic Coma</Disease_Name>
      <Disease_Detail>Hypoglycemic Coma</Disease_Detail>
      <Disease_DB>HYP026</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypoglycemic_coma?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pregnancy Loss</Disease_Name>
      <Disease_Detail>Pregnancy Loss</Disease_Detail>
      <Disease_DB>PRG060</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pregnancy_loss?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Venous Thrombosis, Protection Against</Disease_Name>
      <Disease_Detail>Venous Thrombosis, Protection Against</Disease_Detail>
      <Disease_DB>VNS011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/venous_thrombosis_protection_against?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Esophageal Varix</Disease_Name>
      <Disease_Detail>Esophageal Varix</Disease_Detail>
      <Disease_DB>ESP002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/esophageal_varix?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cerebral Sinovenous Thrombosis</Disease_Name>
      <Disease_Detail>Cerebral Sinovenous Thrombosis</Disease_Detail>
      <Disease_DB>CRB132</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cerebral_sinovenous_thrombosis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemorrhoid</Disease_Name>
      <Disease_Detail>Hemorrhoid</Disease_Detail>
      <Disease_DB>HMR005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemorrhoid?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Non-Arteritic Anterior Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Non-Arteritic Anterior Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>NNR007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/non_arteritic_anterior_ischemic_optic_neuropathy?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prothrombin Deficiency</Disease_Name>
      <Disease_Detail>Prothrombin Deficiency</Disease_Detail>
      <Disease_DB>PRT012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prothrombin_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypersplenism</Disease_Name>
      <Disease_Detail>Hypersplenism</Disease_Detail>
      <Disease_DB>HYP063</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypersplenism?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Peripheral Vertigo</Disease_Name>
      <Disease_Detail>Peripheral Vertigo</Disease_Detail>
      <Disease_DB>PRP028</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/peripheral_vertigo?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Sick Sinus Syndrome</Disease_Name>
      <Disease_Detail>Sick Sinus Syndrome</Disease_Detail>
      <Disease_DB>SCK002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/sick_sinus_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hansen's Disease</Disease_Name>
      <Disease_Detail>Hansen's Disease</Disease_Detail>
      <Disease_DB>HNS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hansens_disease?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatitis E</Disease_Name>
      <Disease_Detail>Hepatitis E</Disease_Detail>
      <Disease_DB>HPT007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatitis_e?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bernard-Soulier Syndrome</Disease_Name>
      <Disease_Detail>Bernard-Soulier Syndrome</Disease_Detail>
      <Disease_DB>BRN019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bernard_soulier_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Compartment Syndrome</Disease_Name>
      <Disease_Detail>Compartment Syndrome</Disease_Detail>
      <Disease_DB>CMP008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/compartment_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Inherited Hypoprothrombinemia</Disease_Name>
      <Disease_Detail>Inherited Hypoprothrombinemia</Disease_Detail>
      <Disease_DB>INH005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/inherited_hypoprothrombinemia?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Choledocholithiasis</Disease_Name>
      <Disease_Detail>Choledocholithiasis</Disease_Detail>
      <Disease_DB>CHL039</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/choledocholithiasis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Venous Thromboembolism</Disease_Name>
      <Disease_Detail>Venous Thromboembolism</Disease_Detail>
      <Disease_DB>VNS010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/venous_thromboembolism?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Warfarin Sensitivity</Disease_Name>
      <Disease_Detail>Warfarin Sensitivity</Disease_Detail>
      <Disease_DB>WRF002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/warfarin_sensitivity?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Porencephaly</Disease_Name>
      <Disease_Detail>Porencephaly</Disease_Detail>
      <Disease_DB>PRN026</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/porencephaly?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Homocysteinemia</Disease_Name>
      <Disease_Detail>Homocysteinemia</Disease_Detail>
      <Disease_DB>HMC014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/homocysteinemia?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Blood Protein Disease</Disease_Name>
      <Disease_Detail>Blood Protein Disease</Disease_Detail>
      <Disease_DB>BLD054</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/blood_protein_disease?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombophilia Due to Thrombin Defect</Disease_Name>
      <Disease_Detail>Thrombophilia</Disease_Detail>
      <Disease_DB>THR092</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombophilia_due_to_thrombin_defect?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Viii Deficiency</Disease_Name>
      <Disease_Detail>Factor Viii Deficiency</Disease_Detail>
      <Disease_DB>FCT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_viii_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Severe Hemophilia a</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>SVR056</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/severe_hemophilia_a?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Liver Failure</Disease_Name>
      <Disease_Detail>Acute Liver Failure</Disease_Detail>
      <Disease_DB>ACT134</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_liver_failure?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cavernous Hemangioma</Disease_Name>
      <Disease_Detail>Cavernous Hemangioma</Disease_Detail>
      <Disease_DB>CVR006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cavernous_hemangioma?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Biphenotypic Leukemia</Disease_Name>
      <Disease_Detail>Acute Biphenotypic Leukemia</Disease_Detail>
      <Disease_DB>ACT095</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_biphenotypic_leukemia?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vulvovaginal Candidiasis</Disease_Name>
      <Disease_Detail>Vulvovaginal Candidiasis</Disease_Detail>
      <Disease_DB>VLV011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vulvovaginal_candidiasis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Abdominal Aortic Aneurysm</Disease_Name>
      <Disease_Detail>Abdominal Aortic Aneurysm</Disease_Detail>
      <Disease_DB>ABD003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/abdominal_aortic_aneurysm?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Viral Hepatitis</Disease_Name>
      <Disease_Detail>Viral Hepatitis</Disease_Detail>
      <Disease_DB>VRL010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/viral_hepatitis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Botulism</Disease_Name>
      <Disease_Detail>Botulism</Disease_Detail>
      <Disease_DB>BTL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/botulism?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>ISC002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ischemic_optic_neuropathy?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Spinal Cord Infarction</Disease_Name>
      <Disease_Detail>Spinal Cord Infarction</Disease_Detail>
      <Disease_DB>SPN185</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/spinal_cord_infarction?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Vii Deficiency</Disease_Name>
      <Disease_Detail>Factor Vii Deficiency</Disease_Detail>
      <Disease_DB>FCT007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_vii_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gastroschisis</Disease_Name>
      <Disease_Detail>Gastroschisis</Disease_Detail>
      <Disease_DB>GST009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastroschisis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pulmonary Embolism</Disease_Name>
      <Disease_Detail>Pulmonary Embolism</Disease_Detail>
      <Disease_DB>PLM033</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pulmonary_embolism?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Intrahepatic Cholestasis</Disease_Name>
      <Disease_Detail>Intrahepatic Cholestasis</Disease_Detail>
      <Disease_DB>INT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/intrahepatic_cholestasis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombophlebitis</Disease_Name>
      <Disease_Detail>Thrombophlebitis</Disease_Detail>
      <Disease_DB>THR016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombophlebitis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatitis B</Disease_Name>
      <Disease_Detail>Hepatitis B</Disease_Detail>
      <Disease_DB>HPT016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatitis_b?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Portal Vein Thrombosis</Disease_Name>
      <Disease_Detail>Portal Vein Thrombosis</Disease_Detail>
      <Disease_DB>PRT018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/portal_vein_thrombosis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pregnancy Loss, Recurrent 2</Disease_Name>
      <Disease_Detail>Pregnancy Loss</Disease_Detail>
      <Disease_DB>PRG096</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pregnancy_loss_recurrent_2?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Antiphospholipid Syndrome</Disease_Name>
      <Disease_Detail>Antiphospholipid Syndrome</Disease_Detail>
      <Disease_DB>ANT006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/antiphospholipid_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Alcoholic Hepatitis</Disease_Name>
      <Disease_Detail>Alcoholic Hepatitis</Disease_Detail>
      <Disease_DB>ALC006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/alcoholic_hepatitis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Arteritic Anterior Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Arteritic Anterior Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>ART110</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/arteritic_anterior_ischemic_optic_neuropathy?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Anterior Spinal Artery Syndrome</Disease_Name>
      <Disease_Detail>Anterior Spinal Artery Syndrome</Disease_Detail>
      <Disease_DB>ANT013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/anterior_spinal_artery_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vein Disease</Disease_Name>
      <Disease_Detail>Vein Disease</Disease_Detail>
      <Disease_DB>VND001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vein_disease?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ischemic Colitis</Disease_Name>
      <Disease_Detail>Ischemic Colitis</Disease_Detail>
      <Disease_DB>ISC015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ischemic_colitis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thromboembolism</Disease_Name>
      <Disease_Detail>Thromboembolism</Disease_Detail>
      <Disease_DB>THR079</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thromboembolism?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Protein S Deficiency</Disease_Name>
      <Disease_Detail>Protein S Deficiency</Disease_Detail>
      <Disease_DB>PRT014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/protein_s_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Post-Thrombotic Syndrome</Disease_Name>
      <Disease_Detail>Post-Thrombotic Syndrome</Disease_Detail>
      <Disease_DB>PST095</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/post_thrombotic_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Malignant Histiocytosis</Disease_Name>
      <Disease_Detail>Malignant Histiocytosis</Disease_Detail>
      <Disease_DB>MLG054</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/malignant_histiocytosis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dysfibrinogenemia</Disease_Name>
      <Disease_Detail>Dysfibrinogenemia</Disease_Detail>
      <Disease_DB>DYS026</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dysfibrinogenemia?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency</Disease_Name>
      <Disease_Detail>Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency</Disease_Detail>
      <Disease_DB>NNT020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neonatal_intrahepatic_cholestasis_caused_by_citrin_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostatic Adenoma</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostatic_adenoma?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Xi Deficiency</Disease_Name>
      <Disease_Detail>Factor Xi Deficiency</Disease_Detail>
      <Disease_DB>FCT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_xi_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pseudotumor Cerebri</Disease_Name>
      <Disease_Detail>Pseudotumor Cerebri</Disease_Detail>
      <Disease_DB>PSD002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pseudotumor_cerebri?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor V Deficiency</Disease_Name>
      <Disease_Detail>Factor V Deficiency</Disease_Detail>
      <Disease_DB>FCT006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_v_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatorenal Syndrome</Disease_Name>
      <Disease_Detail>Hepatorenal Syndrome</Disease_Detail>
      <Disease_DB>HPT014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatorenal_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Anterior Ischemic Optic Neuropathy</Disease_Name>
      <Disease_Detail>Anterior Ischemic Optic Neuropathy</Disease_Detail>
      <Disease_DB>ANT058</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/anterior_ischemic_optic_neuropathy?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Stroke, Ischemic</Disease_Name>
      <Disease_Detail>Stroke</Disease_Detail>
      <Disease_DB>STR067</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/stroke_ischemic?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lymphoplasmacytic Lymphoma</Disease_Name>
      <Disease_Detail>Lymphoplasmacytic Lymphoma</Disease_Detail>
      <Disease_DB>LYM012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lymphoplasmacytic_lymphoma?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neonatal Hemochromatosis</Disease_Name>
      <Disease_Detail>Neonatal Hemochromatosis</Disease_Detail>
      <Disease_DB>NNT016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neonatal_hemochromatosis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Retinal Artery Occlusion</Disease_Name>
      <Disease_Detail>Retinal Artery Occlusion</Disease_Detail>
      <Disease_DB>RTN014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/retinal_artery_occlusion?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Scott Syndrome</Disease_Name>
      <Disease_Detail>Scott Syndrome</Disease_Detail>
      <Disease_DB>SCT005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/scott_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acquired Von Willebrand Syndrome</Disease_Name>
      <Disease_Detail>Acquired Von Willebrand Syndrome</Disease_Detail>
      <Disease_DB>ACQ017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acquired_von_willebrand_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemophilia</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>HMP007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemophilia?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Congenital Afibrinogenemia</Disease_Name>
      <Disease_Detail>Congenital Afibrinogenemia</Disease_Detail>
      <Disease_DB>CNG019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/congenital_afibrinogenemia?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Central Retinal Vein Occlusion</Disease_Name>
      <Disease_Detail>Central Retinal Vein Occlusion</Disease_Detail>
      <Disease_DB>CNT016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/central_retinal_vein_occlusion?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Non-a-E Hepatitis</Disease_Name>
      <Disease_Detail>Non-a-E Hepatitis</Disease_Detail>
      <Disease_DB>NNH002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/non_a_e_hepatitis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Abdominal Tuberculosis</Disease_Name>
      <Disease_Detail>Abdominal Tuberculosis</Disease_Detail>
      <Disease_DB>ABD004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/abdominal_tuberculosis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Binder Syndrome</Disease_Name>
      <Disease_Detail>Binder Syndrome</Disease_Detail>
      <Disease_DB>BND003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/binder_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Warfarin Resistance</Disease_Name>
      <Disease_Detail>Warfarin Resistance</Disease_Detail>
      <Disease_DB>WRF001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/warfarin_resistance?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cortical Blindness</Disease_Name>
      <Disease_Detail>Cortical Blindness</Disease_Detail>
      <Disease_DB>CRT012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cortical_blindness?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Fatty Liver of Pregnancy</Disease_Name>
      <Disease_Detail>Acute Fatty Liver of Pregnancy</Disease_Detail>
      <Disease_DB>ACT099</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_fatty_liver_of_pregnancy?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Liver Disease</Disease_Name>
      <Disease_Detail>Liver Disease</Disease_Detail>
      <Disease_DB>LVR013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/liver_disease?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Citrin Deficiency</Disease_Name>
      <Disease_Detail>Citrin Deficiency</Disease_Detail>
      <Disease_DB>CTR003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/citrin_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Sneddon Syndrome</Disease_Name>
      <Disease_Detail>Sneddon Syndrome</Disease_Detail>
      <Disease_DB>SND002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/sneddon_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Disseminated Intravascular Coagulation</Disease_Name>
      <Disease_Detail>Disseminated Intravascular Coagulation</Disease_Detail>
      <Disease_DB>DSS009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/disseminated_intravascular_coagulation?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatoportal Sclerosis</Disease_Name>
      <Disease_Detail>Hepatoportal Sclerosis</Disease_Detail>
      <Disease_DB>HPT066</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatoportal_sclerosis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prothrombin-Related Thrombophilia</Disease_Name>
      <Disease_Detail>Prothrombin-Related Thrombophilia</Disease_Detail>
      <Disease_DB>PRT045</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prothrombin_related_thrombophilia?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Portal Hypertension</Disease_Name>
      <Disease_Detail>Portal Hypertension</Disease_Detail>
      <Disease_DB>PRT013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/portal_hypertension?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Multifocal Lymphangioendotheliomatosis with Thrombocytopenia</Disease_Name>
      <Disease_Detail>Multifocal Lymphangioendotheliomatosis with Thrombocytopenia</Disease_Detail>
      <Disease_DB>MLT037</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/multifocal_lymphangioendotheliomatosis_with_thrombocytopenia?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Papilledema</Disease_Name>
      <Disease_Detail>Papilledema</Disease_Detail>
      <Disease_DB>PPL021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/papilledema?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Afibrinogenemia</Disease_Name>
      <Disease_Detail>Afibrinogenemia</Disease_Detail>
      <Disease_DB>AFB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/afibrinogenemia?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Xiii Deficiency</Disease_Name>
      <Disease_Detail>Factor Xiii Deficiency</Disease_Detail>
      <Disease_DB>FCT005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_xiii_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mediterranean Spotted Fever</Disease_Name>
      <Disease_Detail>Mediterranean Spotted Fever</Disease_Detail>
      <Disease_DB>MDT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mediterranean_spotted_fever?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Venous Thrombosis</Disease_Name>
      <Disease_Detail>Venous Thrombosis</Disease_Detail>
      <Disease_DB>VNS009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/venous_thrombosis?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemophilia B</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>HMP004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemophilia_b?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombophilia</Disease_Name>
      <Disease_Detail>Thrombophilia</Disease_Detail>
      <Disease_DB>THR015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombophilia?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Antithrombin Iii Deficiency</Disease_Name>
      <Disease_Detail>Antithrombin Iii Deficiency</Disease_Detail>
      <Disease_DB>ANT009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/antithrombin_iii_deficiency?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Central Retinal Artery Occlusion</Disease_Name>
      <Disease_Detail>Central Retinal Artery Occlusion</Disease_Detail>
      <Disease_DB>CNT028</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/central_retinal_artery_occlusion?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hantavirus Pulmonary Syndrome</Disease_Name>
      <Disease_Detail>Hantavirus Pulmonary Syndrome</Disease_Detail>
      <Disease_DB>HNT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hantavirus_pulmonary_syndrome?search=F2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatitis D</Disease_Name>
      <Disease_Detail>Hepatitis D</Disease_Detail>
      <Disease_DB>HPT015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatitis_d?search=F2#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH BCH-10556 AND EXOSITE-DIRECTED PEPTIDE</PDB_Title>
      <PDB_ID>1G37</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1G37</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.</PubMed_Title>
      <Author>Bachand, B., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2001)11:287-290</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11212093?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Native S195A Thrombin with an Unoccupied Active Site</PDB_Title>
      <PDB_ID>1JOU</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1JOU</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03160008</ASD_Ligand>
      <PubMed_Title>The molecular basis of thrombin allostery revealed by a 1.8A structure of the slow form</PubMed_Title>
      <Author>Huntington, J.A., et al.</Author>
      <Journal>Structure(2003)11:469-479</Journal>
      <PubMed_ID>12679024</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES</PDB_Title>
      <PDB_ID>1NRQ</PDB_ID>
      <Resolution>3.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NRQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes.</PubMed_Title>
      <Author>Mathews, I.I., et al.</Author>
      <Journal>Biochemistry(1994)33:3266-3279</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8136362?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN ALPHA-THROMBIN Y225I MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE</PDB_Title>
      <PDB_ID>1B7X</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1B7X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Unexpected crucial role of residue 225 in serine proteases.</PubMed_Title>
      <Author>Guinto, E.R., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1999)96:1852-1857</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10051558?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR</PDB_Title>
      <PDB_ID>1C5L</PDB_ID>
      <Resolution>1.47</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C5L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>Chem.Biol.(2000)7:299-312</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10779411?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Fast form of thrombin mutant R(77a)A bound to PPACK</PDB_Title>
      <PDB_ID>1SFQ</PDB_ID>
      <Resolution>1.91</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SFQ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03160008</ASD_Ligand>
      <PubMed_Title>Molecular dissection of na+ binding to thrombin.</PubMed_Title>
      <Author>Pineda, A.O., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:31842-31853</Journal>
      <PubMed_ID>15152000</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of thrombin bound to heparin</PDB_Title>
      <PDB_ID>1XMN</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XMN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of thrombin bound to heparin</PubMed_Title>
      <Author>Carter, W.J., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:2745-2749</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15548541?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human thrombin chimera with human residues 184a, 186, 186a, 186b, 186c and 222 replaced by murine thrombin equivalents.</PDB_Title>
      <PDB_ID>2OD3</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OD3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis of na+ activation mimicry in murine thrombin.</PubMed_Title>
      <Author>Marino, F., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:16355-16361</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17428793?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms</PDB_Title>
      <PDB_ID>1TMU</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TMU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms.</PubMed_Title>
      <Author>Priestle, J.P., et al.</Author>
      <Journal>Protein Sci.(1993)2:1630-1642</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8251938?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF THROMBIN WITH DESIGNED INHIBITOR 7165</PDB_Title>
      <PDB_ID>1VZQ</PDB_ID>
      <Resolution>1.54</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1VZQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Enantiomerically Pure Thrombin Inhibitors for Exploring the Molecular-Recognition Features of the Oxyanion Hole</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES</PDB_Title>
      <PDB_ID>1NRO</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NRO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes.</PubMed_Title>
      <Author>Mathews, I.I., et al.</Author>
      <Journal>Biochemistry(1994)33:3266-3279</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8136362?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the W215A/E217A Mutant of Human Thrombin (space group P2(1)2(1)2(1))</PDB_Title>
      <PDB_ID>3EE0</PDB_ID>
      <Resolution>2.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EE0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular Basis for the Kinetic Differences of the W215A/E217A Mutant of Human and Murine Thrombin</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of prethrombin-2 mutant S195A in the alternative form</PDB_Title>
      <PDB_ID>3SQE</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3SQE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of prethrombin-2 reveal alternative conformations under identical solution conditions and the mechanism of zymogen activation.</PubMed_Title>
      <Author>Pozzi, N., et al.</Author>
      <Journal>Biochemistry(2011)50:10195-10202</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22049947?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures</PDB_Title>
      <PDB_ID>1EOJ</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1EOJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.</PubMed_Title>
      <Author>Slon-Usakiewicz, J.J., et al.</Author>
      <Journal>Biochemistry(2000)39:2384-2391</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10694407?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG2</PDB_Title>
      <PDB_ID>1A3E</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A3E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Bifunctional peptide boronate inhibitors of thrombin: crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide.</PubMed_Title>
      <Author>Skordalakes, E., et al.</Author>
      <Journal>Biochemistry(1998)37:14420-14427</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9772168?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies.</PDB_Title>
      <PDB_ID>1NO9</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NO9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>DESIGN OF WEAKLY BASIC THROMBIN INHIBITORS INCORPORATING NOVEL P1 BINDING FUNCTIONS: MOLECULAR AND X-RAY CRYSTALLOGRAPHIC STUDIES</PubMed_Title>
      <Author>De Simone, G., et al.</Author>
      <Journal>Biochemistry(2003)42:9013-9021</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12885234?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND P-AMIDINOPHENYLPYRUVATE AT 1.6 ANGSTROMS RESOLUTION</PDB_Title>
      <PDB_ID>1AHT</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AHT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human alpha-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 A resolution.</PubMed_Title>
      <Author>Chen, Z., et al.</Author>
      <Journal>Arch.Biochem.Biophys.(1995)322:198-203</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7574675?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5-AMIDINOINDOLE-4-BENZYLPIPERIDINE INHIBITOR</PDB_Title>
      <PDB_ID>1D4P</PDB_ID>
      <Resolution>2.07</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1D4P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structure of human alpha-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitor.</PubMed_Title>
      <Author>Chirgadze, N.Y., et al.</Author>
      <Journal>Protein Sci.(1997)6:1412-1417</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9232642?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SER195ALA MUTANT OF HUMAN THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A (7-16)</PDB_Title>
      <PDB_ID>1DM4</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DM4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the Ser195Ala mutant of human alpha--thrombin complexed with fibrinopeptide A(7--16): evidence for residual catalytic activity.</PubMed_Title>
      <Author>Krishnan, R., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:406-410</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10739913?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-RAY CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.</PDB_Title>
      <PDB_ID>1H8I</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1H8I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Inhibition of Human Alpha-Thrombin by a Phosphonate Tripeptide Proceeds Via a Metastable Pentacoordinated Phosphorus Intermediate</PubMed_Title>
      <Author>Skordalakes, E., et al.</Author>
      <Journal>J.Mol.Biol.(2001)311:549</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11493008?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-RAY STRUCTURE OF THE HUMAN ALPHA-THROMBIN COMPLEX WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.</PDB_Title>
      <PDB_ID>1H8D</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1H8D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Inhibition of Human Alpha-Thrombin by a Phosphonate Tripeptide Proceeds Via a Metastable Pentacoordinated Phosphorus Intermediate</PubMed_Title>
      <Author>Skordalakes, E., et al.</Author>
      <Journal>J.Mol.Biol.(2001)311:549</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11493008?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>thrombin and P2 pyridine N-oxide inhibitor complex structure</PDB_Title>
      <PDB_ID>1Z71</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Z71</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>P(2) pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold</PubMed_Title>
      <Author>Nantermet, P.G., et al.</Author>
      <Journal>BIOORG.MED.CHEM.LETT.(2005)15:2771-2775</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15911253?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Ternary complex of an orally active thrombin inhibitor with human thrombin and a c-terminal hirudin derived exo-sit inhibitor</PDB_Title>
      <PDB_ID>2ANM</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ANM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety</PubMed_Title>
      <Author>Lange, U.E.W., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:2648-2653</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16460939?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human prethrombin-1</PDB_Title>
      <PDB_ID>3NXP</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NXP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of prethrombin-1.</PubMed_Title>
      <Author>Chen, Z., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:19278-19283</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20974933?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin inhibitors with rigid tripeptidyl aldehydes</PDB_Title>
      <PDB_ID>1CA8</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1CA8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes</PubMed_Title>
      <Author>Krishnan, R., et al.</Author>
      <Journal>Biochemistry(1998)37:12094-12103</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9724521?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>1QJ7</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QJ7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structures of Thrombin Complexed to a Novel Series of Synthetic Inhibitors Containing a 5,5-Trans-Lactone Template</PubMed_Title>
      <Author>Jhoti, H., et al.</Author>
      <Journal>Biochemistry(1999)38:7969</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10387040?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN</PDB_Title>
      <PDB_ID>2HGT</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HGT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.</PubMed_Title>
      <Author>Skrzypczak-Jankun, E., et al.</Author>
      <Journal>J.Mol.Biol.(1991)221:1379-1393</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1942057?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of Thrombin Bound to the Inhibitor FM19</PDB_Title>
      <PDB_ID>3BV9</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BV9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.</PubMed_Title>
      <Author>Nieman, M.T., et al.</Author>
      <Journal>J.Thromb.Haemost.(2008)6:837-845</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18315550?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS</PDB_Title>
      <PDB_ID>1ABJ</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ABJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors.</PubMed_Title>
      <Author>Qiu, X., et al.</Author>
      <Journal>Biochemistry(1992)31:11689-11697</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1445905?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>MOLECULAR BASIS FOR THE INHIBITION OF HUMAN ALPHA-THROMBIN BY THE MACROCYCLIC PEPTIDE CYCLOTHEONAMIDE A</PDB_Title>
      <PDB_ID>1TMB</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TMB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular basis for the inhibition of human alpha-thrombin by the macrocyclic peptide cyclotheonamide A.</PubMed_Title>
      <Author>Maryanoff, B.E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1993)90:8048-8052</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8367461?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the thrombin mutant G193A bound to PPACK</PDB_Title>
      <PDB_ID>1Z8I</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Z8I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Energetic and structural consequences of perturbing Gly-193 in the oxyanion hole of serine proteases</PubMed_Title>
      <Author>Bobofchak, K.M., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:25644-25650</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15890651?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of thrombin mutant Y225P in the E form</PDB_Title>
      <PDB_ID>3S7K</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3S7K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic and Kinetic Evidence of Allostery in a Trypsin-like Protease.</PubMed_Title>
      <Author>Niu, W., et al.</Author>
      <Journal>Biochemistry(2011)50:6301-6307</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21707111?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.</PDB_Title>
      <PDB_ID>1C4U</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C4U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of thrombin complexed with selective non-electrophilic inhibitors having cyclohexyl moieties at P1.</PubMed_Title>
      <Author>Krishnan, R., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:294-303</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10713516?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray structure of the complex between human alpha thrombin and a modified thrombin binding aptamer (mTBA)</PDB_Title>
      <PDB_ID>3QLP</PDB_ID>
      <Resolution>2.14</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QLP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Thrombin-aptamer recognition: a revealed ambiguity.</PubMed_Title>
      <Author>Russo Krauss, I., et al.</Author>
      <Journal>Nucleic Acids Res.(2011)39:7858-7867</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21715374?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystallographic analysis at 3.0-Angstroms resolution of the binding to human thrombin of four active site-directed inhibitors</PDB_Title>
      <PDB_ID>1DWE</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DWE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors.</PubMed_Title>
      <Author>Banner, D.W., et al.</Author>
      <Journal>J.Biol.Chem.(1991)266:20085-20093</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1939071?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN INHIBITOR WITH A RIGID TRIPEPTIDYL ALDEHYDES</PDB_Title>
      <PDB_ID>1BA8</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BA8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes.</PubMed_Title>
      <Author>Krishnan, R., et al.</Author>
      <Journal>Biochemistry(1998)37:12094-12103</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9724521?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human thrombin mutant W215A/E217A in complex with the extracellular fragment of human PAR1</PDB_Title>
      <PDB_ID>3HKJ</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HKJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mechanism of the Anticoagulant Activity of Thrombin Mutant W215A/E217A.</PubMed_Title>
      <Author>Gandhi, P.S., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:24098-24105</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19586901?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>1QJ1</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QJ1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structures of Thrombin Complexed to a Novel Series of Synthetic Inhibitors Containing a 5,5-Trans-Lactone Template</PubMed_Title>
      <Author>Jhoti, H., et al.</Author>
      <Journal>Biochemistry(1999)38:7969</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10387040?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR</PDB_Title>
      <PDB_ID>1C5O</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C5O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>Chem.Biol.(2000)7:299-312</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10779411?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL BICYCLIC LACTAM INHIBITOR</PDB_Title>
      <PDB_ID>1JWT</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1JWT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues.</PubMed_Title>
      <Author>Levesque, S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2001)11:3161-3164</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11720865?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of thrombin inhibited by synthetic cyanopeptide analogue RA-1008</PDB_Title>
      <PDB_ID>1YPL</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YPL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and X-ray crystal structures of human thrombin with synthetic cyanopeptide-analogues.</PubMed_Title>
      <Author>Radau, G., et al.</Author>
      <Journal>Pharmazie(2007)62:83-88</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17341023?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human alpha-thrombin*RWJ-51438 complex at 1.7 A</PDB_Title>
      <PDB_ID>1DOJ</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DOJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of human alpha-thrombin complexed with RWJ-51438 at 1.7 A: unusual perturbation of the 60A-60I insertion loop.</PubMed_Title>
      <Author>Recacha, R., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:1395-1400</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11053836?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Inhibitor-free human thrombin mutant C191A-C220A</PDB_Title>
      <PDB_ID>2PGB</PDB_ID>
      <Resolution>1.54</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PGB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Important role of the cys-191 cys-220 disulfide bond in thrombin function and allostery</PubMed_Title>
      <Author>Bush-Pelc, L.A., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:27165-27170</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17636263?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6</PDB_Title>
      <PDB_ID>1IHT</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IHT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the complex of human alpha-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6.</PubMed_Title>
      <Author>Zdanov, A., et al.</Author>
      <Journal>Proteins(1993)17:252-265</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8272424?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN</PDB_Title>
      <PDB_ID>1GJ4</PDB_ID>
      <Resolution>1.81</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GJ4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>Chem.Biol.(2001)8:1107-1121</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11731301?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROARG-OH</PDB_Title>
      <PDB_ID>1LHC</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LHC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs.</PubMed_Title>
      <Author>Weber, P.C., et al.</Author>
      <Journal>Biochemistry(1995)34:3750-3757</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7893672?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE STRUCTURE OF ALPHA-THROMBIN INHIBITED BY A 15-MER SINGLE-STRANDED DNA APTAMER</PDB_Title>
      <PDB_ID>1HUT</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HUT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer.</PubMed_Title>
      <Author>Padmanabhan, K., et al.</Author>
      <Journal>J.Biol.Chem.(1993)268:17651-17654</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8102368?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN THROMBIN-INHIBITOR COMPLEX</PDB_Title>
      <PDB_ID>1K21</PDB_ID>
      <Resolution>1.86</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1K21</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition.</PubMed_Title>
      <Author>Dullweber, F., et al.</Author>
      <Journal>J.Mol.Biol.(2001)313:593-614</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11676542?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures</PDB_Title>
      <PDB_ID>1EOL</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1EOL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.</PubMed_Title>
      <Author>Slon-Usakiewicz, J.J., et al.</Author>
      <Journal>Biochemistry(2000)39:2384-2391</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10694407?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Exploring Thrombin S1-pocket</PDB_Title>
      <PDB_ID>2ZFF</PDB_ID>
      <Resolution>1.47</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZFF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exploring Thrombin S1-pocket</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-SUBSTRATE COMPLEX</PDB_Title>
      <PDB_ID>1DE7</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DE7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Interaction of the factor XIII activation peptide with alpha -thrombin. Crystal structure of its enzyme-substrate analog complex.</PubMed_Title>
      <Author>Sadasivan, C., et al.</Author>
      <Journal>J.Biol.Chem.(2000)275:36942-36948</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10956659?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>2C8X</PDB_ID>
      <Resolution>2.17</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C8X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors</PubMed_Title>
      <Author>Howard, N., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:1346</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16480269?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Exploring thrombin S3 pocket</PDB_Title>
      <PDB_ID>2ZHF</PDB_ID>
      <Resolution>1.98</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZHF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exploring thrombin S3 pocket</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT</PDB_Title>
      <PDB_ID>1AWH</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AWH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel natural product 5,5-trans-lactone inhibitors of human alpha-thrombin: mechanism of action and structural studies.</PubMed_Title>
      <Author>Weir, M.P., et al.</Author>
      <Journal>Biochemistry(1998)37:6645-6657</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9578548?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human thrombin with residues 145-150 of murine thrombin.</PDB_Title>
      <PDB_ID>3R3G</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3R3G</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03160008</ASD_Ligand>
      <PubMed_Title>Rigidification of the autolysis loop enhances Na(+) binding to thrombin.</PubMed_Title>
      <Author>Pozzi, N., et al.</Author>
      <Journal>Biophys.Chem.(2011)159:6-13</Journal>
      <PubMed_ID>21536369</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibitor Complex</PDB_Title>
      <PDB_ID>1YPJ</PDB_ID>
      <Resolution>1.78</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YPJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A simple protocol to estimate differences in protein binding affinity for enantiomers without prior resolution of racemates</PubMed_Title>
      <Author>Fokkens, J., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2006)45:985-989</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16374786?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-N-BUTYL-AMIDINO-GLYCINE-OH</PDB_Title>
      <PDB_ID>1LHE</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LHE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs.</PubMed_Title>
      <Author>Weber, P.C., et al.</Author>
      <Journal>Biochemistry(1995)34:3750-3757</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7893672?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibitor</PDB_Title>
      <PDB_ID>3EQ0</PDB_ID>
      <Resolution>1.53</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EQ0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Thrombin Inhibition</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>orally active thrombin inhibitors in complex with thrombin and an exosite decapeptide</PDB_Title>
      <PDB_ID>2ANK</PDB_ID>
      <Resolution>2.46</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ANK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety</PubMed_Title>
      <Author>Lange, U.E.W., et al.</Author>
      <Journal>BIOORG.MED.CHEM.LETT.(2006)16:2648-2653</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16460939?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN ALPHA-THROMBIN Y225P MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE</PDB_Title>
      <PDB_ID>1THP</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1THP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Unexpected crucial role of residue 225 in serine proteases.</PubMed_Title>
      <Author>Guinto, E.R., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1999)96:1852-1857</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10051558?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of thrombin in complex with inhibitor 15</PDB_Title>
      <PDB_ID>3C1K</PDB_ID>
      <Resolution>1.84</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3C1K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.</PubMed_Title>
      <Author>Isaacs, R.C., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:2062-2066</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18291642?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin in complex with inhibitor</PDB_Title>
      <PDB_ID>2PKS</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PKS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, synthesis and biological evaluation of thrombin inhibitors based on a pyridine scaffold.</PubMed_Title>
      <Author>Blomberg, D., et al.</Author>
      <Journal>Org.Biomol.Chem.(2007)5:2599-2605</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18019535?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>2C90</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C90</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors</PubMed_Title>
      <Author>Howard, N., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:1346</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16480269?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE CRYSTAL STRUCTURE OF ALPHA-THROMBIN-HIRUNORM IV COMPLEX REVEALS A NOVEL SPECIFICITY SITE RECOGNITION MODE.</PDB_Title>
      <PDB_ID>4THN</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4THN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structure of alpha-thrombin-hirunorm IV complex reveals a novel specificity site recognition mode.</PubMed_Title>
      <Author>Lombardi, A., et al.</Author>
      <Journal>Protein Sci.(1999)8:91-95</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10210187?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibitor Complex</PDB_Title>
      <PDB_ID>1YPG</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YPG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A simple protocol to estimate differences in protein binding affinity for enantiomers without prior resolution of racemates</PubMed_Title>
      <Author>Fokkens, J., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2006)45:985-989</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16374786?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS</PDB_Title>
      <PDB_ID>1ABI</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ABI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors.</PubMed_Title>
      <Author>Qiu, X., et al.</Author>
      <Journal>Biochemistry(1992)31:11689-11697</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1445905?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX</PDB_Title>
      <PDB_ID>1DX5</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DX5</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03160008</ASD_Ligand>
      <PubMed_Title>Structural Basis for the Anticoagulant Activity of the Thrombin-Thrombomodulin Complex</PubMed_Title>
      <Author>Fuentes-Prior, P., et al.</Author>
      <Journal>Nature(2000)404:518</Journal>
      <PubMed_ID>10761923</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the potent anticoagulant thrombin mutant W215A/E217A in free form</PDB_Title>
      <PDB_ID>1TQ0</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TQ0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket</PubMed_Title>
      <Author>Pineda, A.O., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:39824-39828</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15252033?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS</PDB_Title>
      <PDB_ID>1DWD</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DWD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors.</PubMed_Title>
      <Author>Banner, D.W., et al.</Author>
      <Journal>J.Biol.Chem.(1991)266:20085-20093</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1939071?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN COMPLEXED WITH HIRUGEN AND A BETA-STRAND MIMETIC INHIBITOR</PDB_Title>
      <PDB_ID>1A46</PDB_ID>
      <Resolution>2.12</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A46</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Bound structures of novel P3-P1' beta-strand mimetic inhibitors of thrombin.</PubMed_Title>
      <Author>St Charles, R., et al.</Author>
      <Journal>J.Med.Chem.(1999)42:1376-1383</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10212123?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the procoagulant fast form of thrombin</PDB_Title>
      <PDB_ID>1SG8</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SG8</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03160008</ASD_Ligand>
      <PubMed_Title>Molecular dissection of na+ binding to thrombin.</PubMed_Title>
      <Author>Pineda, A.O., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:31842-31853</Journal>
      <PubMed_ID>15152000</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of prethrombin-2 mutant S195A in the the open form</PDB_Title>
      <PDB_ID>3SQH</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3SQH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of prethrombin-2 reveal alternative conformations under identical solution conditions and the mechanism of zymogen activation.</PubMed_Title>
      <Author>Pozzi, N., et al.</Author>
      <Journal>Biochemistry(2011)50:10195-10202</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22049947?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROORNITHINE-OH</PDB_Title>
      <PDB_ID>1LHG</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LHG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs.</PubMed_Title>
      <Author>Weber, P.C., et al.</Author>
      <Journal>Biochemistry(1995)34:3750-3757</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7893672?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Staphylocoagulase-Prethrombin-2 complex</PDB_Title>
      <PDB_ID>1NU9</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NU9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation</PubMed_Title>
      <Author>Friedrich, R., et al.</Author>
      <Journal>NATURE(2003)425:535-539</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14523451?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS</PDB_Title>
      <PDB_ID>1TMT</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TMT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms.</PubMed_Title>
      <Author>Priestle, J.P., et al.</Author>
      <Journal>Protein Sci.(1993)2:1630-1642</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8251938?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin inhibitor complex</PDB_Title>
      <PDB_ID>1KTT</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KTT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of novel potent nonpeptide thrombin inhibitors.</PubMed_Title>
      <Author>Hauel, N.H., et al.</Author>
      <Journal>J.Med.Chem.(2002)45:1757-1766</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11960487?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human ppack-thrombin</PDB_Title>
      <PDB_ID>2HPQ</PDB_ID>
      <Resolution>3.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HPQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human PPACK-thrombin.</PubMed_Title>
      <Author>Arni, R.K., et al.</Author>
      <Journal>Biochemistry(1993)32:4727-4737</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8387813?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.</PDB_Title>
      <PDB_ID>1C4V</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C4V</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of thrombin complexed with selective non-electrophilic inhibitors having cyclohexyl moieties at P1.</PubMed_Title>
      <Author>Krishnan, R., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:294-303</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10713516?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human alpha-thrombin complexed with a peptidyl pyridinium methyl ketone containing bivalent inhibitor</PDB_Title>
      <PDB_ID>1HBT</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HBT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of a peptidyl pyridinium methyl ketone inhibitor with thrombin.</PubMed_Title>
      <Author>Rehse, P.H., et al.</Author>
      <Journal>Biochemistry(1995)34:11537-11544</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7547884?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Exploring Thrombin S1 pocket</PDB_Title>
      <PDB_ID>2ZDV</PDB_ID>
      <Resolution>1.72</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZDV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exploring Thrombin S1 pocket</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>thrombin in complex with selective macrocyclic inhibitor at 1.8A</PDB_Title>
      <PDB_ID>1NM6</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NM6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of potent and selective macrocyclic thrombin inhibitors</PubMed_Title>
      <Author>Nantermet, P.G., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2003)13:2781-2784</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12873514?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin:suramin complex</PDB_Title>
      <PDB_ID>3BF6</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BF6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and thermodynamic analysis of thrombin:suramin interaction in solution and crystal phases.</PubMed_Title>
      <Author>Lima, L.M., et al.</Author>
      <Journal>Biochim.Biophys.Acta(2009)1794:873-881</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19332154?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition by Pyridin Derivatives</PDB_Title>
      <PDB_ID>3QTV</PDB_ID>
      <Resolution>1.63</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QTV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Thrombin Inhibition</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR</PDB_Title>
      <PDB_ID>1OYT</PDB_ID>
      <Resolution>1.67</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OYT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A Fluorine Scan of Thrombin Inhibitors to Map the Fluorophilicity/Fluorophobicity of an Enzyme Active Site: Evidence for CF...C=O Interactions.</PubMed_Title>
      <Author>Olsen, J.A., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2003)42:2507-2511</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12800172?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN INHIBITOR FROM THEONALLA, CYCLOTHEANAMIDE-BASED MACROCYCLIC TRIPEPTIDE MOTIF</PDB_Title>
      <PDB_ID>1AY6</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AY6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel thrombin inhibitors that are based on a macrocyclic tripeptide motif</PubMed_Title>
      <Author>Greco, M.N., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(1996)6:2947-2952</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8367461?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the thrombin mutant D221A/D222K</PDB_Title>
      <PDB_ID>1TWX</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TWX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the thrombin mutant D221A/D222K: the Asp222:Arg187 ion-pair stabilizes the fast form</PubMed_Title>
      <Author>Pineda, A.O., et al.</Author>
      <Journal>Biophys.Chem.(2004)112:253-256</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15572256?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human thrombin mutant N143P in E* form</PDB_Title>
      <PDB_ID>3JZ2</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JZ2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mutant N143P reveals how Na+ activates thrombin</PubMed_Title>
      <Author>Niu, W., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:36175-36185</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19846563?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of thrombin-variegin complex: Insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors</PDB_Title>
      <PDB_ID>3B23</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B23</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of thrombin in complex with s-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors</PubMed_Title>
      <Author>Koh, C.Y., et al.</Author>
      <Journal>Plos One(2011)6:e26367-e26367</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22053189?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE REFINED 1.9 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN: INTERACTION WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE AND SIGNIFICANCE OF THE TYR-PRO-PRO-TRP INSERTION SEGMENT</PDB_Title>
      <PDB_ID>1PPB</PDB_ID>
      <Resolution>1.92</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PPB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment.</PubMed_Title>
      <Author>Bode, W., et al.</Author>
      <Journal>EMBO J.(1989)8:3467-3475</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/2583108?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN THROMBIN WITH ACTIVE SITE N-METHYL-D PHENYLALANYL-N-[5-(AMINOIMINOMETHYL)AMINO]-1-{{BENZOTHIAZOLYL)CARBONYL] BUTYL]-L-PROLINAMIDE TRIFLUROACETATE AND EXOSITE-HIRUGEN</PDB_Title>
      <PDB_ID>1TBZ</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TBZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1' binding site.</PubMed_Title>
      <Author>Matthews, J.H., et al.</Author>
      <Journal>Biophys.J.(1996)71:2830-2839</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8913620?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX</PDB_Title>
      <PDB_ID>2JH0</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JH0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Sulfonamide-Related Conformational Effects and Their Importance in Structure-Based Design.</PubMed_Title>
      <Author>Senger, S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2007)17:2931</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17336062?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human alpha-thrombin in complex with suramin</PDB_Title>
      <PDB_ID>2H9T</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2H9T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and thermodynamic analysis of thrombin:suramin interaction in solution and crystal phases.</PubMed_Title>
      <Author>Lima, L.M., et al.</Author>
      <Journal>Biochim.Biophys.Acta(2009)1794:873-881</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19332154?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the slow form of thrombin in a self_inhibited conformation</PDB_Title>
      <PDB_ID>3BEI</PDB_ID>
      <Resolution>1.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BEI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural identification of the pathway of long-range communication in an allosteric enzyme.</PubMed_Title>
      <Author>Gandhi, P.S., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2008)105:1832-1837</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18250335?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of thrombin mutant delta(146-149e) in the free form</PDB_Title>
      <PDB_ID>3GIC</PDB_ID>
      <Resolution>1.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GIC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Stabilization of the E* form turns thrombin into an anticoagulant.</PubMed_Title>
      <Author>Bah, A., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:20034-20040</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19473969?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibitor Complex</PDB_Title>
      <PDB_ID>1KTS</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KTS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of novel potent nonpeptide thrombin inhibitors.</PubMed_Title>
      <Author>Hauel, N.H., et al.</Author>
      <Journal>J.Med.Chem.(2002)45:1757-1766</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11960487?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED INHIBITOR</PDB_Title>
      <PDB_ID>2CN0</PDB_ID>
      <Resolution>1.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2CN0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mapping the Fluorophilicity of a Hydrophobic Pocket: Synthesis and Biological Evaluation of Tricyclic Thrombin Inhibitors Directing Fluorinated Alkyl Groups Into the P Pocket</PubMed_Title>
      <Author>Hoffmann-Roder, A., et al.</Author>
      <Journal>Chemmedchem(2006)1:1205</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17001711?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON X-RAY MODEL OF DNA)</PDB_Title>
      <PDB_ID>1HAP</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HAP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>An ambiguous structure of a DNA 15-mer thrombin complex.</PubMed_Title>
      <Author>Padmanabhan, K., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(1996)52:272-282</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15299700?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>2-(2-Chloro-6-Fluorophenyl)Acetamides as Potent Thrombin Inhibitors</PDB_Title>
      <PDB_ID>2R2M</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2R2M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>2-(2-Chloro-6-Fluorophenyl)Acetamides as Potent Thrombin Inhibitors</PubMed_Title>
      <Author>Lee, L., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2007)17:6266-6269</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17889527?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition</PDB_Title>
      <PDB_ID>2ZHQ</PDB_ID>
      <Resolution>1.96</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZHQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry.</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2010)397:1042-1054</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20156458?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6</PDB_Title>
      <PDB_ID>1IHS</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IHS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the complex of human alpha-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6.</PubMed_Title>
      <Author>Zdanov, A., et al.</Author>
      <Journal>Proteins(1993)17:252-265</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8272424?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human ppack-thrombin</PDB_Title>
      <PDB_ID>2HPP</PDB_ID>
      <Resolution>3.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HPP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human PPACK-thrombin.</PubMed_Title>
      <Author>Arni, R.K., et al.</Author>
      <Journal>Biochemistry(1993)32:4727-4737</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8387813?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Understanding Thrombin Inhibition</PDB_Title>
      <PDB_ID>3DUX</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DUX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2009)391:552-564</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19520086?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition by Pyridin Derivatives</PDB_Title>
      <PDB_ID>3P17</PDB_ID>
      <Resolution>1.43</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P17</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Thrombin Inhibition</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Exploring thrombin S3 pocket</PDB_Title>
      <PDB_ID>2ZG0</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZG0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exploring thrombin S3 pocket</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Structure of thrombin mutant Y225P in the E* form</PDB_Title>
      <PDB_ID>3S7H</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3S7H</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic and Kinetic Evidence of Allostery in a Trypsin-like Protease.</PubMed_Title>
      <Author>Niu, W., et al.</Author>
      <Journal>Biochemistry(2011)50:6301-6307</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21707111?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS</PDB_Title>
      <PDB_ID>1DWB</PDB_ID>
      <Resolution>3.16</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DWB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors.</PubMed_Title>
      <Author>Banner, D.W., et al.</Author>
      <Journal>J.Biol.Chem.(1991)266:20085-20093</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1939071?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis of thrombin mediated factor V activation: essential role of the hirudin-like sequence Glu666-Glu672 for processing at the heavy chain-B domain junction</PDB_Title>
      <PDB_ID>3P6Z</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P6Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis of thrombin-mediated factor V activation: the Glu666-Glu672 sequence is critical for processing at the heavy chain-B domain junction.</PubMed_Title>
      <Author>Corral-Rodriguez, Bock, et al.</Author>
      <Journal>Blood(2011)117:7164-7173</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21555742?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin-Hirugen-L405,426</PDB_Title>
      <PDB_ID>1MUE</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MUE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.</PubMed_Title>
      <Author>Burgey, C.S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2003)13:1353-1357</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12657281?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG1</PDB_Title>
      <PDB_ID>1A3B</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A3B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Bifunctional peptide boronate inhibitors of thrombin: crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide.</PubMed_Title>
      <Author>Skordalakes, E., et al.</Author>
      <Journal>Biochemistry(1998)37:14420-14427</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9772168?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors</PDB_Title>
      <PDB_ID>1O2G</PDB_ID>
      <Resolution>1.58</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1O2G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Elaborate Manifold of Short Hydrogen Bond Arrays Mediating   Binding of Active Site-Directed Serine Protease Inhibitors</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>J.Mol.Biol.(2003)329:93-120</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12742021?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE</PDB_Title>
      <PDB_ID>1GHV</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GHV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>J.Mol.Biol.(2001)307:1451-1486</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11292354?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin in complex with an azafluorenyl inhibitor 23b</PDB_Title>
      <PDB_ID>1ZRB</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZRB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>9-hydroxyazafluorenes and their use in thrombin inhibitors</PubMed_Title>
      <Author>Stauffer, K.J., et al.</Author>
      <Journal>J.Med.Chem.(2005)48:2282-2293</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15801822?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ACTIVE SITE THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>1WBG</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1WBG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Fragment-Based Lead Discovery Using X-Ray Crystallography</PubMed_Title>
      <Author>Hartshorn, M.J., et al.</Author>
      <Journal>J.Med.Chem.(2005)48:403</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15658854?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN</PDB_Title>
      <PDB_ID>1HAH</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HAH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin.</PubMed_Title>
      <Author>Vijayalakshmi, J., et al.</Author>
      <Journal>Protein Sci.(1994)3:2254-2271</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7756983?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Exploring Thrombin S1 Pocket</PDB_Title>
      <PDB_ID>2ZF0</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZF0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exploring Thrombin S1 pocket</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2</PDB_Title>
      <PDB_ID>1D3Q</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1D3Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors.</PubMed_Title>
      <Author>Chirgadze, N.Y., et al.</Author>
      <Journal>Protein Sci.(2000)9:29-36</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10739244?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the complex between thrombin and the central E region of fibrin</PDB_Title>
      <PDB_ID>2A45</PDB_ID>
      <Resolution>3.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2A45</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for sequential cleavage of fibrinopeptides upon fibrin assembly.</PubMed_Title>
      <Author>Pechik, I., et al.</Author>
      <Journal>Biochemistry(2006)45:3588-3597</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16533041?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN THROMBIN COMPLEX WITH HIRUDIN VARIANT</PDB_Title>
      <PDB_ID>1HXF</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HXF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The molecular environment of the Na+ binding site of thrombin.</PubMed_Title>
      <Author>Zhang, E., et al.</Author>
      <Journal>Biophys.Chem.(1997)63:185-200</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9108691?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Orally active thrombin inhibitors</PDB_Title>
      <PDB_ID>2FES</PDB_ID>
      <Resolution>2.42</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FES</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety.</PubMed_Title>
      <Author>Mack, H., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:2641-2647</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16517159?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Exploring thrombin S3 pocket</PDB_Title>
      <PDB_ID>2ZFR</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZFR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exploring thrombin S3 pocket</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN</PDB_Title>
      <PDB_ID>1BCU</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BCU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray and spectrophotometric studies of the binding of proflavin to the S1 specificity pocket of human alpha-thrombin.</PubMed_Title>
      <Author>Conti, E., et al.</Author>
      <Journal>FEBS Lett.(1998)425:229-233</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9559654?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>D-Phe-Pro-Arg-Type Thrombin Inhibitor</PDB_Title>
      <PDB_ID>1NZQ</PDB_ID>
      <Resolution>2.18</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NZQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>D-Phe-Pro-Arg type thrombin inhibitors: unexpected selectivity by modification of the P1 moiety</PubMed_Title>
      <Author>Lange, U.E., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2003)13:2029-2033</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12781189?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN THROMBIN COMPLEXED WITH FRAGMENT-BASED SMALL MOLECULES OCCUPYING THE S1 POCKET</PDB_Title>
      <PDB_ID>2BVS</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BVS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of Thrombin Inhibitor Fragments from Chemical Microarray Screening</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibitor Complex</PDB_Title>
      <PDB_ID>1YPK</PDB_ID>
      <Resolution>1.78</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YPK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A Simple Protocol To Estimate Differences in Protein Binding Affinity for Enantiomers without Prior Resolution of Racemates</PubMed_Title>
      <Author>Fokkens, J., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2006)45:985-989</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16374786?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR</PDB_Title>
      <PDB_ID>1THR</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1THR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor.</PubMed_Title>
      <Author>Qiu, X., et al.</Author>
      <Journal>J.Biol.Chem.(1993)268:20318-20326</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8376390?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE INTERACTION OF THROMBIN WITH FIBRINOGEN: A STRUCTURAL BASIS FOR ITS SPECIFICITY</PDB_Title>
      <PDB_ID>1FPH</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FPH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The interaction of thrombin with fibrinogen. A structural basis for its specificity.</PubMed_Title>
      <Author>Stubbs, M.T., et al.</Author>
      <Journal>Eur.J.Biochem.(1992)206:187-195</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1587268?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROLYS-OH</PDB_Title>
      <PDB_ID>1LHD</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LHD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs.</PubMed_Title>
      <Author>Weber, P.C., et al.</Author>
      <Journal>Biochemistry(1995)34:3750-3757</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7893672?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES</PDB_Title>
      <PDB_ID>1BB0</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BB0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes.</PubMed_Title>
      <Author>Krishnan, R., et al.</Author>
      <Journal>Biochemistry(1998)37:12094-12103</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9724521?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition by Pyridin Derivatives</PDB_Title>
      <PDB_ID>3QX5</PDB_ID>
      <Resolution>1.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QX5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Thrombin Inhibition</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Nonbasic Thrombin Inhibitor Complex</PDB_Title>
      <PDB_ID>1XM1</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XM1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Nonbasic Thrombin Inhibitor Complex</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition</PDB_Title>
      <PDB_ID>2ZNK</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZNK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry.</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2010)397:1042-1054</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20156458?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of thrombin bound to the extracellular fragment of PAR1</PDB_Title>
      <PDB_ID>3BEF</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BEF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural identification of the pathway of long-range communication in an allosteric enzyme.</PubMed_Title>
      <Author>Gandhi, P.S., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2008)105:1832-1837</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18250335?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-4-[(AMINOIMINOMETHYL)AMINO]-N-[[1-[3-HYDROXY-2-[(2-NAPHTHALENYLSULFONYL)AMINO]-1-OXOPROPYL]-2-PYRROLIDINYL] METHYL]BUTANAMIDE (BMS-186282)</PDB_Title>
      <PDB_ID>1BMM</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BMM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090.</PubMed_Title>
      <Author>Malley, M.F., et al.</Author>
      <Journal>Protein Sci.(1996)5:221-228</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8745399?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inibition</PDB_Title>
      <PDB_ID>2ZFP</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZFP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2009)391:552-564</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19520086?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR</PDB_Title>
      <PDB_ID>1BTH</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BTH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The thrombin E192Q-BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulin.</PubMed_Title>
      <Author>van de Locht, A., et al.</Author>
      <Journal>EMBO J.(1997)16:2977-2984</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9214615?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4</PDB_Title>
      <PDB_ID>1D3D</PDB_ID>
      <Resolution>2.04</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1D3D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors</PubMed_Title>
      <Author>Chirgadze, N.Y., et al.</Author>
      <Journal>Protein Sci.(2000)9:29-36</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10739244?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of thrombin in complex with fibrinogen gamma' peptide</PDB_Title>
      <PDB_ID>2HWL</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HWL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of thrombin in complex with fibrinogen gamma' peptide.</PubMed_Title>
      <Author>Pineda, A.O., et al.</Author>
      <Journal>Biophys.Chem.(2007)125:556-559</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16962697?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the thrombin mutant G193P bound to PPACK</PDB_Title>
      <PDB_ID>1Z8J</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Z8J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Energetic and structural consequences of perturbing Gly-193 in the oxyanion hole of serine proteases</PubMed_Title>
      <Author>Bobofchak, K.M., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:25644-25650</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15890651?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cyanofluorophenylacetamides as Orally Efficacious Thrombin Inhibitors</PDB_Title>
      <PDB_ID>3C27</PDB_ID>
      <Resolution>2.18</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3C27</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Cyanofluorophenylacetamides as Orally Efficacious Thrombin Inhibitors</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human thrombin mutant D102N in complex with the extracellular fragment of human PAR4.</PDB_Title>
      <PDB_ID>3QDZ</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QDZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis of thrombin-protease-receptor interactions</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Mechanism of Sulfotyrosine-Mediated Glycoprotein Ib Interaction with Two Distinct alpha-Thrombin Sites</PDB_Title>
      <PDB_ID>3PMH</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PMH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Binding of alpha-thrombin to surface-anchored platelet glycoprotein Ib(alpha) sulfotyrosines through a two-site mechanism involving exosite I.</PubMed_Title>
      <Author>Zarpellon, A., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2011)108:8628-8633</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21555542?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>2.1 Angstrom structure of a nonproductive complex between antithrombin, synthetic heparin mimetic SR123781 and two S195A thrombin molecules</PDB_Title>
      <PDB_ID>2B5T</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2B5T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation.</PubMed_Title>
      <Author>Johnson, D.J., et al.</Author>
      <Journal>J.Biol.Chem.(2006)281:35478-35486</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16973611?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTOPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1</PDB_Title>
      <PDB_ID>1D9I</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1D9I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of thrombin complexed with selective non-electrophilic inhibitors having cyclohexyl moieties at P1.</PubMed_Title>
      <Author>Krishnan, R., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:294-303</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10713516?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Thrombin in Complex with L-378,622</PDB_Title>
      <PDB_ID>1MU6</PDB_ID>
      <Resolution>1.99</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MU6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.</PubMed_Title>
      <Author>Burgey, C.S., et al.</Author>
      <Journal>J.Med.Chem.(2003)46:461-473</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12570369?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>DESIGN AND DISCOVERY OF NOVEL, POTENT THROMBIN INHIBITORS WITH A SOLUBILIZING CATIONIC P1-P2-LINKER</PDB_Title>
      <PDB_ID>2BXU</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and Discovery of Novel, Potent Pyrazinone-Based Thrombin Inhibitors with a Solubilizing P1-P2-Linker</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition</PDB_Title>
      <PDB_ID>2ZIQ</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZIQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Understanding Thrombin Inhibition</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2770.</PDB_Title>
      <PDB_ID>8KME</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=8KME</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of thrombin retro-inhibited with SEL2711 and SEL2770 as they relate to factor Xa binding.</PubMed_Title>
      <Author>Mochalkin, I., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(1999)55:785-793</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10089309?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition</PDB_Title>
      <PDB_ID>3D49</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3D49</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Understanding Thrombin Inhibition</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR</PDB_Title>
      <PDB_ID>1C5N</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C5N</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>Chem.Biol.(2000)7:299-312</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10779411?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN</PDB_Title>
      <PDB_ID>1A5G</PDB_ID>
      <Resolution>2.06</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A5G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Bound structures of novel P3-P1' beta-strand mimetic inhibitors of thrombin.</PubMed_Title>
      <Author>St Charles, R., et al.</Author>
      <Journal>J.Med.Chem.(1999)42:1376-1383</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10212123?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the anticoagulant thrombin mutant W215A/E217A bound to PPACK</PDB_Title>
      <PDB_ID>1TQ7</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TQ7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket</PubMed_Title>
      <Author>Pineda, A.O., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:39824-39828</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15252033?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>DESIGN AND DISCOVERY OF NOVEL, POTENT THROMBIN INHIBITORS WITH A SOLUBILIZING CATIONIC P1-P2-LINKER</PDB_Title>
      <PDB_ID>2BXT</PDB_ID>
      <Resolution>1.83</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BXT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and Discovery of Novel, Potent Pyrazinone-Based Thrombin Inhibitors with a Solubilizing P1-P2-Linker</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROVAL</PDB_Title>
      <PDB_ID>1AIX</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AIX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships.</PubMed_Title>
      <Author>Bode, W., et al.</Author>
      <Journal>Protein Sci.(1992)1:426-471</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1304349?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>1.9 angstrom crytal structure of wild-type human thrombin in the sodium free state</PDB_Title>
      <PDB_ID>2AFQ</PDB_ID>
      <Resolution>1.93</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AFQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of wild-type human thrombin in the Na+-free state</PubMed_Title>
      <Author>Johnson, D.J.D., et al.</Author>
      <Journal>Biochem.J.(2005)392:21-28</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16201969?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)</PDB_Title>
      <PDB_ID>1O5G</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1O5G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>J.Mol.Biol.(2004)344:527-547</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15522303?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY</PDB_Title>
      <PDB_ID>1AD8</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AD8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety.</PubMed_Title>
      <Author>Malikayil, J.A., et al.</Author>
      <Journal>Biochemistry(1997)36:1034-1040</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9033393?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>thrombin in complex with selective macrocyclic inhibitor</PDB_Title>
      <PDB_ID>1NT1</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NT1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of potent and selective macrocyclic thrombin inhibitors</PubMed_Title>
      <Author>Nantermet, P.G., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2003)13:2781-2784</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12873514?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of thrombin in 400 mM potassium chloride</PDB_Title>
      <PDB_ID>2A0Q</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2A0Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Thrombin Functions through Its RGD Sequence in a Non-canonical Conformation.</PubMed_Title>
      <Author>Papaconstantinou, M.E., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:29393-29396</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15998637?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ACTIVE SITE THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>1WAY</PDB_ID>
      <Resolution>2.02</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1WAY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Fragment-Based Lead Discovery Using X-Ray Crystallography</PubMed_Title>
      <Author>Hartshorn, M.J., et al.</Author>
      <Journal>J.Med.Chem.(2005)48:403</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15658854?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN ALPHA-THROMBIN Y225F MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE</PDB_Title>
      <PDB_ID>2THF</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2THF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Unexpected crucial role of residue 225 in serine proteases.</PubMed_Title>
      <Author>Guinto, E.R., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1999)96:1852-1857</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10051558?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC STRUCTURE OF HUMAN GAMMA-THROMBIN</PDB_Title>
      <PDB_ID>2HNT</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HNT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic structure of human gamma-thrombin.</PubMed_Title>
      <Author>Rydel, T.J., et al.</Author>
      <Journal>J.Biol.Chem.(1994)269:22000-22006</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8071320?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Discovery and Clinical Evaluation of RWJ-671818, a Thrombin Inhibitor with an Oxyguanidine P1 Motif</PDB_Title>
      <PDB_ID>3LDX</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LDX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery and Clinical Evaluation of RWJ-671818, a Thrombin Inhibitor with an Oxyguanidine P1 Motif</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>SELECTIVE NON-ELECTROPHILIC THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>1C4Y</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C4Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of thrombin complexed with selective non-electrophilic inhibitors having cyclohexyl moieties at P1.</PubMed_Title>
      <Author>Krishnan, R., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:294-303</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10713516?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN THROMBIN-INHIBITOR COMPLEX</PDB_Title>
      <PDB_ID>1K22</PDB_ID>
      <Resolution>1.93</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1K22</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition.</PubMed_Title>
      <Author>Dullweber, F., et al.</Author>
      <Journal>J.Mol.Biol.(2001)313:593-614</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11676542?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-1-(AMINOIMINOMETHYL)-N-[[1-[N-[(2-NAPHTHALENYLSULFONYL)-L-SERYL]-PYRROLIDINYL]METHYL]-3-PIPERIDENECARBOXAMIDE (BMS-189090)</PDB_Title>
      <PDB_ID>1BMN</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BMN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090.</PubMed_Title>
      <Author>Malley, M.F., et al.</Author>
      <Journal>Protein Sci.(1996)5:221-228</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8745399?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES</PDB_Title>
      <PDB_ID>1C1W</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C1W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design of potent selective zinc-mediated serine protease inhibitors.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>Nature(1998)391:608-612</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9468142?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of thrombin in complex with compound 14b</PDB_Title>
      <PDB_ID>1TA6</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TA6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin  inhibitors that utilize nonbasic groups in the P1 position</PubMed_Title>
      <Author>Tucker, T.J., et al.</Author>
      <Journal>J.Med.Chem.(1998)41:3210-3219</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9703466?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Staphylocoagulase-Thrombin Complex</PDB_Title>
      <PDB_ID>1NU7</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NU7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation</PubMed_Title>
      <Author>Friedrich, R., et al.</Author>
      <Journal>NATURE(2003)425:535-539</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14523451?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Complex of Platelet Receptor GPIb-alpha and Human alpha-Thrombin</PDB_Title>
      <PDB_ID>1OOK</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OOK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Modulation of alpha-thrombin function by distinct interactions with platelet   glycoprotein Ibalpha</PubMed_Title>
      <Author>Celikel, R., et al.</Author>
      <Journal>Science(2003)301:218-221</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12855810?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN-HIRUGEN-GW420128 TERNARY COMPLEX AT 1.39A RESOLUTION</PDB_Title>
      <PDB_ID>2UUK</PDB_ID>
      <Resolution>1.39</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2UUK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Determination of Protonation States in Proteins.</PubMed_Title>
      <Author>Ahmed, H.U., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2007)63:906</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17642517?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human thrombin mutant N143P in E:Na+ form</PDB_Title>
      <PDB_ID>3JZ1</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JZ1</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03160008</ASD_Ligand>
      <PubMed_Title>Mutant N143P reveals how Na+ activates thrombin</PubMed_Title>
      <Author>Niu, W., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:36175-36185</Journal>
      <PubMed_ID>19846563</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin in complex with Inhibitor</PDB_Title>
      <PDB_ID>2ZC9</PDB_ID>
      <Resolution>1.58</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZC9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2009)391:552-564</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19520086?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX STRUCTURE OF HUMAN THROMBIN WITH N-METHYL-ARGININE INHIBITOR</PDB_Title>
      <PDB_ID>1EB1</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1EB1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Methyl Group of N(Alpha)(Me)Arg-Containing Peptides Disturbs the Active-Site Geometry of Thrombin, Impairing Efficient Cleavage</PubMed_Title>
      <Author>Friedrich, R., et al.</Author>
      <Journal>J.Mol.Biol.(2002)316:869</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11884127?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES</PDB_Title>
      <PDB_ID>1NRS</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NRS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes.</PubMed_Title>
      <Author>Mathews, I.I., et al.</Author>
      <Journal>Biochemistry(1994)33:3266-3279</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8136362?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>DESIGN AND DISCOVERY OF NOVEL, POTENT THROMBIN INHIBITORS WITH A SOLUBILIZING CATIONIC P1-P2-LINKER</PDB_Title>
      <PDB_ID>2BVX</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BVX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and Discovery of Novel, Potent Pyrazinone-Based Thrombin Inhibitors with a Solubilizing P1-P2-Linker</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>1QJ6</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QJ6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structures of Thrombin Complexed to a Novel Series of Synthetic Inhibitors Containing a 5,5-Trans-Lactone Template</PubMed_Title>
      <Author>Jhoti, H., et al.</Author>
      <Journal>Biochemistry(1999)38:7969</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10387040?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition by Pyridin Derivatives</PDB_Title>
      <PDB_ID>3QWC</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QWC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Thrombin Inhibition</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of sulfo-hirudin complexed to thrombin</PDB_Title>
      <PDB_ID>2PW8</PDB_ID>
      <Resolution>1.84</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PW8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of a biosynthetic sulfo-hirudin complexed to thrombin.</PubMed_Title>
      <Author>Liu, C.C., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2007)129:10648-10649</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17685615?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURES OF THROMBIN WITH THIAZOLE-CONTAINING INHIBITORS: PROBES OF THE S1' BINDING SITE</PDB_Title>
      <PDB_ID>1A4W</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A4W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1' binding site.</PubMed_Title>
      <Author>Matthews, J.H., et al.</Author>
      <Journal>Biophys.J.(1996)71:2830-2839</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8913620?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Bisphenylic Thrombin Inhibitors</PDB_Title>
      <PDB_ID>3DHK</PDB_ID>
      <Resolution>1.73</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DHK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2009)391:552-564</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19520086?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the anticoagulant slow form of thrombin</PDB_Title>
      <PDB_ID>1SGI</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SGI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular dissection of na+ binding to thrombin.</PubMed_Title>
      <Author>Pineda, A.O., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:31842-31853</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15152000?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition</PDB_Title>
      <PDB_ID>2ZI2</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZI2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry.</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2010)397:1042-1054</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20156458?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR</PDB_Title>
      <PDB_ID>1THS</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1THS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor.</PubMed_Title>
      <Author>Qiu, X., et al.</Author>
      <Journal>J.Biol.Chem.(1993)268:20318-20326</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8376390?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin in complex with Benzothiazole Guanidine</PDB_Title>
      <PDB_ID>3PO1</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PO1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of Benzothiazole Guanidines as Novel Inhibitors of Thrombin and Trypsin IV</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES</PDB_Title>
      <PDB_ID>1NRP</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NRP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes.</PubMed_Title>
      <Author>Mathews, I.I., et al.</Author>
      <Journal>Biochemistry(1994)33:3266-3279</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8136362?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Na-free Thrombin in Complex with Thrombomodulin</PDB_Title>
      <PDB_ID>3GIS</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GIS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular basis of thrombomodulin activation of slow thrombin</PubMed_Title>
      <Author>Adams, T.E., et al.</Author>
      <Journal>J.Thromb.Haemost.(2009)7:1688-1695</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19656282?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>crystal structue of Thrombin in complex with a potent P1 heterocycle-Aryl based inhibitor</PDB_Title>
      <PDB_ID>1SL3</PDB_ID>
      <Resolution>1.81</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SL3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors</PubMed_Title>
      <Author>Young, M.B., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:2995-3008</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15163182?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human alpha-thrombin complexed with N-(methylsulfonyl)-D-phenylalanyl-N-((1-carbamimidoyl-4-piperidinyl)methyl)-l-prolinamide (BMS-189664)</PDB_Title>
      <PDB_ID>3TU7</PDB_ID>
      <Resolution>2.49</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TU7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular design and structure-activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.</PubMed_Title>
      <Author>Das, J., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2002)12:45-49</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11738570?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE REFINED STRUCTURE OF THE HIRUDIN-THROMBIN COMPLEX</PDB_Title>
      <PDB_ID>4HTC</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4HTC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Refined structure of the hirudin-thrombin complex.</PubMed_Title>
      <Author>Rydel, T.J., et al.</Author>
      <Journal>J.Mol.Biol.(1991)221:583-601</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1920434?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis of thrombin-mediated factor V activation: essential role of the hirudin-like sequence Glu666-Glu672 for processing at the heavy chain-B domain junction</PDB_Title>
      <PDB_ID>3P70</PDB_ID>
      <Resolution>2.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P70</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis of thrombin-mediated factor V activation: the Glu666-Glu672 sequence is critical for processing at the heavy chain-B domain junction.</PubMed_Title>
      <Author>Corral-Rodriguez, M.A., et al.</Author>
      <Journal>Blood(2011)117:7164-7173</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21555742?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>thrombin in complex with inhibitor</PDB_Title>
      <PDB_ID>2BDY</PDB_ID>
      <Resolution>1.61</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BDY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.</PubMed_Title>
      <Author>Hanessian, S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:1032-1036</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16290930?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN</PDB_Title>
      <PDB_ID>1B5G</PDB_ID>
      <Resolution>2.07</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1B5G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Bound structures of novel P3-P1' beta-strand mimetic inhibitors of thrombin.</PubMed_Title>
      <Author>St Charles, R., et al.</Author>
      <Journal>J.Med.Chem.(1999)42:1376-1383</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10212123?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystallographic structures of Thrombin complexed with Thrombin receptor peptides: Existence of expected and novel binding modes</PDB_Title>
      <PDB_ID>1NRR</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NRR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes.</PubMed_Title>
      <Author>Mathews, I.I., et al.</Author>
      <Journal>Biochemistry(1994)33:3266-3279</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8136362?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED SYNTHETIC INHIBITOR</PDB_Title>
      <PDB_ID>1QUR</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QUR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and evaluation of novel bivalent thrombin inhibitors based on amidinophenylalanines.</PubMed_Title>
      <Author>Steinmetzer, T., et al.</Author>
      <Journal>Eur.J.Biochem.(1999)265:598-605</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10504391?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin in complex with an oxazolopyridine inhibitor 2</PDB_Title>
      <PDB_ID>1ZGV</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZGV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.</PubMed_Title>
      <Author>Deng, J.Z., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2005)15:4411-4416</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16137886?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Slow form of Thrombin Bound with PPACK</PDB_Title>
      <PDB_ID>1SHH</PDB_ID>
      <Resolution>1.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SHH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular dissection of na+ binding to thrombin.</PubMed_Title>
      <Author>Pineda, A.O., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:31842-31853</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15152000?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN WITH 3-CYCLE WITH F</PDB_Title>
      <PDB_ID>2V3O</PDB_ID>
      <Resolution>1.79</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2V3O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Fluorine in Pharmaceuticals: Looking Beyond Intuition.</PubMed_Title>
      <Author>Mueller, K., et al.</Author>
      <Journal>Science(2007)317:1881</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17901324?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of thrombin inhibited by synthetic cyanopeptide analogue RA-1014</PDB_Title>
      <PDB_ID>1YPM</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YPM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and X-ray crystal structures of human thrombin with synthetic cyanopeptide-analogues.</PubMed_Title>
      <Author>Radau, G., et al.</Author>
      <Journal>Pharmazie(2007)62:83-88</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17341023?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibitor Complex</PDB_Title>
      <PDB_ID>1YPE</PDB_ID>
      <Resolution>1.81</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YPE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A simple protocol to estimate differences in protein binding affinity for enantiomers without prior resolution of racemates</PubMed_Title>
      <Author>Fokkens, J., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2006)45:985-989</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16374786?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human thrombin mutant C191A-C220A in complex with the inhibitor PPACK</PDB_Title>
      <PDB_ID>2PGQ</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PGQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Important role of the cys-191 cys-220 disulfide bond in thrombin function and allostery</PubMed_Title>
      <Author>Bush-Pelc, L.A., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:27165-27170</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17636263?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS</PDB_Title>
      <PDB_ID>1DWC</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DWC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors.</PubMed_Title>
      <Author>Banner, D.W., et al.</Author>
      <Journal>J.Biol.Chem.(1991)266:20085-20093</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1939071?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Thrombin complexed with a d-Phe-Pro-Arg-type Inhibitor and a C-terminal Hirudin derived exo-site inhibitor</PDB_Title>
      <PDB_ID>1O0D</PDB_ID>
      <Resolution>2.44</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1O0D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>D-Phe-Pro-Arg type thrombin inhibitors: unexpected selectivity by modification of the P1 moiety</PubMed_Title>
      <Author>Lange, U.E., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2003)13:2029-2033</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12781189?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE STRUCTURE OF A NONADECAPEPTIDE OF THE FIFTH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN</PDB_Title>
      <PDB_ID>1HLT</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HLT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a nonadecapeptide of the fifth EGF domain of thrombomodulin complexed with thrombin.</PubMed_Title>
      <Author>Mathews, I.I., et al.</Author>
      <Journal>Biochemistry(1994)33:13547-13552</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7947765?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the anticoagulant slow form of thrombin</PDB_Title>
      <PDB_ID>1MH0</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MH0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the anticoagulant slow form of thrombin</PubMed_Title>
      <Author>Pineda, A.O., et al.</Author>
      <Journal>J.Biol.Chem.(2002)277:40177-40180</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12205081?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>thrombin-hirugen_l-378,650</PDB_Title>
      <PDB_ID>1MU8</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MU8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.</PubMed_Title>
      <Author>Burgey, C.S., et al.</Author>
      <Journal>J.Med.Chem.(2003)46:461-473</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12570369?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ACTIVE SITE MIMETIC INHIBITION OF THROMBIN</PDB_Title>
      <PDB_ID>1FPC</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FPC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Active-site mimetic inhibition of thrombin.</PubMed_Title>
      <Author>Mathews, I.I., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(1995)51:550-559</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15299843?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>1QHR</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QHR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template.</PubMed_Title>
      <Author>Jhoti, H., et al.</Author>
      <Journal>Biochemistry(1999)38:7969-7977</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10387040?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human meizothrombin desF1</PDB_Title>
      <PDB_ID>3E6P</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E6P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Na(+) binding to meizothrombin desF1.</PubMed_Title>
      <Author>Papaconstantinou, M.E., et al.</Author>
      <Journal>Cell.Mol.Life Sci.(2008)65:3688-3697</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18854941?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of thrombin in complex with inhibitor</PDB_Title>
      <PDB_ID>3DA9</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DA9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Compounds binding to the S2-S3 pockets of thrombin.</PubMed_Title>
      <Author>Nilsson, M., et al.</Author>
      <Journal>J.Med.Chem.(2009)52:2708-2715</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19371038?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>1.6 A structure of the PCI-thrombin-heparin complex</PDB_Title>
      <PDB_ID>3B9F</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B9F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex.</PubMed_Title>
      <Author>Li, W., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2008)105:4661-4666</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18362344?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE HUMAN ALPHA-THROMBIN-HAEMADIN COMPLEX: AN EXOSITE II-BINDING INHIBITOR</PDB_Title>
      <PDB_ID>1E0F</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E0F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of the Human Alpha-Thrombin-Haemadin Complex: An Exosite II-Binding Inhibitor</PubMed_Title>
      <Author>Richardson, J.L., et al.</Author>
      <Journal>Embo J.(2000)19:5650</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11060016?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Novel Non-Covalent Thrombin Inhibitors Incorporating P1 4,5,6,7-Tetrahydrobenzothiazole Arginine Side Chain Mimetics</PDB_Title>
      <PDB_ID>1SB1</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SB1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel non-covalent thrombin inhibitors incorporating P(1) 4,5,6,7-tetrahydrobenzothiazole arginine side chain mimetics</PubMed_Title>
      <Author>Marinko, P., et al.</Author>
      <Journal>Eur.J.Med.Chem.(2004)39:257-265</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15051174?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>2.5A Structure of Anticoagulant Thrombin Variant E217K</PDB_Title>
      <PDB_ID>1RD3</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RD3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of Anticoagulant Thrombin Variant E217K Provides Insights into Thrombin Allostery</PubMed_Title>
      <Author>Carter, W.J., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:26387-26394</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15075325?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>BOVINE THROMBIN--BM51.1011 COMPLEX</PDB_Title>
      <PDB_ID>1UVS</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1UVS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design.</PubMed_Title>
      <Author>Engh, R.A., et al.</Author>
      <Journal>Structure(1996)4:1353-1362</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8939759?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A INHIBITOR</PDB_Title>
      <PDB_ID>2CF8</PDB_ID>
      <Resolution>1.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2CF8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Multipolar Interactions in the D Pocket of Thrombin: Large Differences between Tricyclic Imide and Lactam Inhibitors.</PubMed_Title>
      <Author>Schweizer, E., et al.</Author>
      <Journal>Org.Biomol.Chem.(2006)4:2364</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16763681?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(N,N-DIMETHYLCARBAMOYL)-ALPHA-AZALYSINE</PDB_Title>
      <PDB_ID>1UMA</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1UMA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human alpha-thrombin inhibition by the active site titrant N alpha-(N,N-dimethylcarbamoyl)-alpha-azalysine p-nitrophenyl ester: a comparative kinetic and X-ray crystallographic study.</PubMed_Title>
      <Author>Nardini, M., et al.</Author>
      <Journal>J.Mol.Biol.(1996)258:851-859</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8637015?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>orally active thrombin inhibitors</PDB_Title>
      <PDB_ID>2FEQ</PDB_ID>
      <Resolution>2.44</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FEQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety</PubMed_Title>
      <Author>Mack, H., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:2641-2647</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16517159?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN</PDB_Title>
      <PDB_ID>1HAI</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HAI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin.</PubMed_Title>
      <Author>Vijayalakshmi, J., et al.</Author>
      <Journal>Protein Sci.(1994)3:2254-2271</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7756983?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN</PDB_Title>
      <PDB_ID>1HGT</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HGT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.</PubMed_Title>
      <Author>Skrzypczak-Jankun, E., et al.</Author>
      <Journal>J.Mol.Biol.(1991)221:1379-1393</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1942057?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR</PDB_Title>
      <PDB_ID>1A61</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A61</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Bound structures of novel P3-P1' beta-strand mimetic inhibitors of thrombin.</PubMed_Title>
      <Author>St Charles, R., et al.</Author>
      <Journal>J.Med.Chem.(1999)42:1376-1383</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10212123?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROMPG</PDB_Title>
      <PDB_ID>1AI8</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AI8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships.</PubMed_Title>
      <Author>Bode, W., et al.</Author>
      <Journal>Protein Sci.(1992)1:426-471</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1304349?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ACTIVE SITE MIMETIC INHIBITION OF THROMBIN</PDB_Title>
      <PDB_ID>3HAT</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HAT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Active-site mimetic inhibition of thrombin.</PubMed_Title>
      <Author>Mathews, I.I., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(1995)51:550-559</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15299843?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SERINE PROTEASE</PDB_Title>
      <PDB_ID>1HXE</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HXE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The molecular environment of the Na+ binding site of thrombin.</PubMed_Title>
      <Author>Zhang, E., et al.</Author>
      <Journal>Biophys.Chem.(1997)63:185-200</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9108691?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN INHIBITOR COMPLEX</PDB_Title>
      <PDB_ID>1G30</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1G30</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.</PubMed_Title>
      <Author>Nar, H., et al.</Author>
      <Journal>Structure(2001)9:29-38</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11342132?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN-HIRUGEN-GW473178 TERNARY COMPLEX AT 1.32A RESOLUTION</PDB_Title>
      <PDB_ID>2UUJ</PDB_ID>
      <Resolution>1.32</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2UUJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Determination of Protonation States in Proteins.</PubMed_Title>
      <Author>Ahmed, H.U., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2007)63:906</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17642517?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX</PDB_Title>
      <PDB_ID>2JH5</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JH5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Sulfonamide-Related Conformational Effects and Their Importance in Structure-Based Design.</PubMed_Title>
      <Author>Senger, S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2007)17:2931</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17336062?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE</PDB_Title>
      <PDB_ID>1GHX</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GHX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>J.Mol.Biol.(2001)307:1451-1486</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11292354?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>KNOBLE Inhibitor</PDB_Title>
      <PDB_ID>3EGK</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EGK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>KNOBLE: a knowledge-based approach for the design and synthesis of readily accessible small-molecule chemical probes to test protein binding</PubMed_Title>
      <Author>Gerlach, C., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2007)46:9105-9109</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17955562?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES</PDB_Title>
      <PDB_ID>1NRN</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NRN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes.</PubMed_Title>
      <Author>Mathews, I.I., et al.</Author>
      <Journal>Biochemistry(1994)33:3266-3279</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8136362?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the slow form of thrombin in a self-inhibited conformation</PDB_Title>
      <PDB_ID>2GP9</PDB_ID>
      <Resolution>1.87</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2GP9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of thrombin in a self-inhibited conformation.</PubMed_Title>
      <Author>Pineda, A.O., et al.</Author>
      <Journal>J.Biol.Chem.(2006)281:32922-32928</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16954215?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>2C8W</PDB_ID>
      <Resolution>1.96</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C8W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors</PubMed_Title>
      <Author>Howard, N., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:1346</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16480269?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Exploring thrombin S3 pocket</PDB_Title>
      <PDB_ID>2ZFQ</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZFQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exploring thrombin S3 pocket</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human thrombin mutant S195A in complex with the extracellular fragment of human PAR1</PDB_Title>
      <PDB_ID>3LU9</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LU9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1.</PubMed_Title>
      <Author>Gandhi, P.S., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:15393-15398</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20236938?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>2C8Z</PDB_ID>
      <Resolution>2.14</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C8Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors</PubMed_Title>
      <Author>Howard, N., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:1346</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16480269?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-HOMOLYS-OH</PDB_Title>
      <PDB_ID>1LHF</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LHF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs.</PubMed_Title>
      <Author>Weber, P.C., et al.</Author>
      <Journal>Biochemistry(1995)34:3750-3757</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7893672?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN-HIRUGEN BINARY COMPLEX AT 1.26A RESOLUTION</PDB_Title>
      <PDB_ID>2UUF</PDB_ID>
      <Resolution>1.26</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2UUF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Determination of Protonation States in Proteins.</PubMed_Title>
      <Author>Ahmed, H.U., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2007)63:906</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17642517?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN WITH 3-CYCLE NO F</PDB_Title>
      <PDB_ID>2V3H</PDB_ID>
      <Resolution>1.79</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2V3H</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Fluorine in Pharmaceuticals: Looking Beyond Intuition.</PubMed_Title>
      <Author>Mueller, K., et al.</Author>
      <Journal>Science(2007)317:1881</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17901324?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE</PDB_Title>
      <PDB_ID>1GHW</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GHW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>J.Mol.Biol.(2001)307:1451-1486</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11292354?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin</PDB_Title>
      <PDB_ID>1T4V</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1T4V</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis</PubMed_Title>
      <Author>Lu, T., et al.</Author>
      <Journal>BIOORG.MED.CHEM.LETT.(2004)14:3727-3731</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15203151?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN INHIBITOR COMPLEX</PDB_Title>
      <PDB_ID>1G32</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1G32</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.</PubMed_Title>
      <Author>Nar, H., et al.</Author>
      <Journal>Structure(2001)9:29-38</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11342132?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Understanding Thrombin Inhibition</PDB_Title>
      <PDB_ID>3DT0</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DT0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Understanding Thrombin Inhibition</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of an RNA aptamer bound to human thrombin</PDB_Title>
      <PDB_ID>3DD2</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DD2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of an RNA aptamer bound to thrombin.</PubMed_Title>
      <Author>Long, S.B., et al.</Author>
      <Journal>Rna(2008)14:2504-2512</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18971322?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ALPHA-THROMBIN COMPLEXED WITH HIRUGEN</PDB_Title>
      <PDB_ID>1TOM</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TOM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis, evaluation, and crystallographic analysis of L-371,912: A potent and selective active-site thrombin inhibitor.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition</PDB_Title>
      <PDB_ID>2ZGB</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZGB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry.</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2010)397:1042-1054</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20156458?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Exploring thrombin S3 pocket</PDB_Title>
      <PDB_ID>2ZHE</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZHE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exploring thrombin S3 pocket</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES</PDB_Title>
      <PDB_ID>1C1U</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C1U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design of potent selective zinc-mediated serine protease inhibitors.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>Nature(1998)391:608-612</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9468142?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1</PDB_Title>
      <PDB_ID>1D3T</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1D3T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors.</PubMed_Title>
      <Author>Chirgadze, N.Y., et al.</Author>
      <Journal>Protein Sci.(2000)9:29-36</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10739244?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition by Pyridin Derivatives</PDB_Title>
      <PDB_ID>3QTO</PDB_ID>
      <Resolution>1.52</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QTO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Thrombin Inhibition</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE</PDB_Title>
      <PDB_ID>1GHY</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GHY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>J.Mol.Biol.(2001)307:1451-1486</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11292354?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The allosteric E*-E equilibrium is a key property of the trypsin fold</PDB_Title>
      <PDB_ID>3QGN</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QGN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic and kinetic evidence of allostery in a trypsin-like protease.</PubMed_Title>
      <Author>Niu, W., et al.</Author>
      <Journal>Biochemistry(2011)50:6301-6307</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21707111?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX</PDB_Title>
      <PDB_ID>2JH6</PDB_ID>
      <Resolution>2.21</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JH6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Sulfonamide-Related Conformational Effects and Their Importance in Structure-Based Design.</PubMed_Title>
      <Author>Senger, S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2007)17:2931</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17336062?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF A RETRO-BINDING PEPTIDE INHIBITOR COMPLEXED WITH HUMAN ALPHA-THROMBIN</PDB_Title>
      <PDB_ID>1HDT</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HDT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a retro-binding peptide inhibitor complexed with human alpha-thrombin.</PubMed_Title>
      <Author>Tabernero, L., et al.</Author>
      <Journal>J.Mol.Biol.(1995)246:14-20</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7853394?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Bisphenylic Thrombin Inhibitors</PDB_Title>
      <PDB_ID>2ZO3</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZO3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2009)391:552-564</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19520086?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN:HIRUNORM V COMPLEX</PDB_Title>
      <PDB_ID>5GDS</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=5GDS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.</PubMed_Title>
      <Author>De Simone, G., et al.</Author>
      <Journal>Protein Sci.(1998)7:243-253</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9521099?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Prethombin-2/Fragment-2 Complex</PDB_Title>
      <PDB_ID>3K65</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3K65</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Zymogenizing a Zymogen - The Crystal Structure of the F2-Prethrombin2 Complex</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition</PDB_Title>
      <PDB_ID>2ZGX</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZGX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2009)391:552-564</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19520086?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>2C93</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C93</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors</PubMed_Title>
      <Author>Howard, N., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:1346</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16480269?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN</PDB_Title>
      <PDB_ID>1HAG</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HAG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin.</PubMed_Title>
      <Author>Vijayalakshmi, J., et al.</Author>
      <Journal>Protein Sci.(1994)3:2254-2271</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7756983?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human thrombin-in complex with UB-THR10</PDB_Title>
      <PDB_ID>3BIU</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BIU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Thermodynamic Inhibition Profile of a Cyclopentyl and a Cyclohexyl Derivative towards Thrombin: The Same but for Different Reasons</PubMed_Title>
      <Author>Gerlach, C., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2007)46:8511-8514</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17902081?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THROMBIN INHIBITORS</PDB_Title>
      <PDB_ID>2C8Y</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C8Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors</PubMed_Title>
      <Author>Howard, N., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:1346</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16480269?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES</PDB_Title>
      <PDB_ID>1C1V</PDB_ID>
      <Resolution>1.98</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C1V</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design of potent selective zinc-mediated serine protease inhibitors.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>Nature(1998)391:608-612</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9468142?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Heparin Cofactor II-S195A Thrombin Complex</PDB_Title>
      <PDB_ID>1JMO</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1JMO</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03160008</ASD_Ligand>
      <PubMed_Title>Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism.</PubMed_Title>
      <Author>Baglin, T.P., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2002)99:11079-11084</Journal>
      <PubMed_ID>12169660</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTROPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1</PDB_Title>
      <PDB_ID>1D6W</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1D6W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of thrombin complexed with selective non-electrophilic inhibitors having cyclohexyl moieties at P1.</PubMed_Title>
      <Author>Krishnan, R., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:294-303</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10713516?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human thrombin-in complex with UB-THR11</PDB_Title>
      <PDB_ID>3BIV</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BIV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Thermodynamic Inhibition Profile of a Cyclopentyl and a Cyclohexyl Derivative towards Thrombin: The Same but for Different Reasons</PubMed_Title>
      <Author>Gerlach, C., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2007)46:8511-8514</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17902081?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN INHIBITION BY EOC-D-PHE-PRO-AZALYS-ONP</PDB_Title>
      <PDB_ID>1AE8</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AE8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human alpha-thrombin inhibition by the highly selective compounds N-ethoxycarbonyl-D-Phe-Pro-alpha-azaLys p-nitrophenyl ester and N-carbobenzoxy-Pro-alpha-azaLys p-nitrophenyl ester: a kinetic, thermodynamic and X-ray crystallographic study.</PubMed_Title>
      <Author>De Simone, G., et al.</Author>
      <Journal>J.Mol.Biol.(1997)269:558-569</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9217260?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2711.</PDB_Title>
      <PDB_ID>7KME</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=7KME</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of thrombin retro-inhibited with SEL2711 and SEL2770 as they relate to factor Xa binding.</PubMed_Title>
      <Author>Mochalkin, I., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(1999)55:785-793</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10089309?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ALPHA-THROMBIN COMPLEX WITH SULFATED HIRUDIN (RESIDUES 54-65) AND L-ARGININE TEMPLATE INHIBITOR CS107</PDB_Title>
      <PDB_ID>1W7G</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1W7G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, Synthesis and Evaluation of Graftable Thrombin Inhibitors for the Preparation of Blood-Compatible Polymer Materials.</PubMed_Title>
      <Author>Salvagnini, C., et al.</Author>
      <Journal>Org.Biomol.Chem.(2005)3:4209</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16294249?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE-MIMETIC INHIBITOR</PDB_Title>
      <PDB_ID>1QBV</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QBV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes.</PubMed_Title>
      <Author>Bone, R., et al.</Author>
      <Journal>J.Med.Chem.(1998)41:2068-2075</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9622548?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>thrombin in complex with an oxazolopyridine inhibitor 21</PDB_Title>
      <PDB_ID>1ZGI</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZGI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.</PubMed_Title>
      <Author>Deng, J.Z., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2005)15:4411-4416</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16137886?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-RAY STRUCTURE OF THE COMPLEX OF HUMAN ALPHA THROMBIN WITH THE INHIBITOR SDZ 229-357</PDB_Title>
      <PDB_ID>1BHX</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BHX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Rational design, synthesis, and X-ray structure of selective noncovalent thrombin inhibitors.</PubMed_Title>
      <Author>Wagner, J., et al.</Author>
      <Journal>J.Med.Chem.(1998)41:3664-3674</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9733491?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of thrombin inhibited by AERUGINOSIN298-A from a BLUE-GREEN ALGA</PDB_Title>
      <PDB_ID>1A2C</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A2C</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of Thrombin Inhibited by Aeruginosin 298-A from a Blue-Green Alga</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND ALPHA-THROMBIN AT 2.6A</PDB_Title>
      <PDB_ID>1P8V</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1P8V</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of the GpIbalpha-Thrombin Complex Essential for Platelet Aggregation</PubMed_Title>
      <Author>Dumas, J.J., et al.</Author>
      <Journal>Science(2003)301:222-226</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12855811?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT</PDB_Title>
      <PDB_ID>1AWF</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AWF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel natural product 5,5-trans-lactone inhibitors of human alpha-thrombin: mechanism of action and structural studies.</PubMed_Title>
      <Author>Weir, M.P., et al.</Author>
      <Journal>Biochemistry(1998)37:6645-6657</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9578548?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A INHIBITOR</PDB_Title>
      <PDB_ID>2CF9</PDB_ID>
      <Resolution>1.79</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2CF9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Multipolar Interactions in the D Pocket of Thrombin: Large Differences between Tricyclic Imide and Lactam Inhibitors.</PubMed_Title>
      <Author>Schweizer, E., et al.</Author>
      <Journal>Org.Biomol.Chem.(2006)4:2364</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16763681?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN</PDB_Title>
      <PDB_ID>1GJ5</PDB_ID>
      <Resolution>1.73</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GJ5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>Chem.Biol.(2001)8:1107-1121</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11731301?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin</PDB_Title>
      <PDB_ID>1T4U</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1T4U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis</PubMed_Title>
      <Author>Lu, T., et al.</Author>
      <Journal>BIOORG.MED.CHEM.LETT.(2004)14:3727-3731</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15203151?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Orally Active Thrombin Inhibitors in Complex with Thrombin Inh12</PDB_Title>
      <PDB_ID>2A2X</PDB_ID>
      <Resolution>2.44</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2A2X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety</PubMed_Title>
      <Author>Lange, U.E.W., et al.</Author>
      <Journal>BIOORG.MED.CHEM.LETT.(2006)16:2648-2653</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16460939?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF A DIVALENT INHIBITOR WITH THROMBIN</PDB_Title>
      <PDB_ID>1DIT</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DIT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic.</PubMed_Title>
      <Author>Krishnan, R., et al.</Author>
      <Journal>Protein Sci.(1996)5:422-433</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8868478?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin in complex with natural product inhibitor Oscillarin</PDB_Title>
      <PDB_ID>1RIW</PDB_ID>
      <Resolution>2.04</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RIW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The N-acyloxyiminium ion aza-Prins route to octahydroindoles: total synthesis and structural confirmation of the antithrombotic marine natural product oscillarin</PubMed_Title>
      <Author>Hanessian, S., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2004)126:6064-6071</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15137772?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin Inhibition</PDB_Title>
      <PDB_ID>3F68</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3F68</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2009)391:552-564</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19520086?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Exploring Thrombin S1 pocket</PDB_Title>
      <PDB_ID>2ZDA</PDB_ID>
      <Resolution>1.73</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZDA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin</PubMed_Title>
      <Author>Baum, B., et al.</Author>
      <Journal>J.Mol.Biol.(2009)391:552-564</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19520086?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ALPHA-THROMBIN INHIBITION BY CBZ-PRO-AZALYS-ONP</PDB_Title>
      <PDB_ID>1AFE</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AFE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human alpha-thrombin inhibition by the highly selective compounds N-ethoxycarbonyl-D-Phe-Pro-alpha-azaLys p-nitrophenyl ester and N-carbobenzoxy-Pro-alpha-azaLys p-nitrophenyl ester: a kinetic, thermodynamic and X-ray crystallographic study.</PubMed_Title>
      <Author>De Simone, G., et al.</Author>
      <Journal>J.Mol.Biol.(1997)269:558-569</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9217260?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN THROMBIN COMPLEXED WITH FRAGMENT-BASED SMALL MOLECULES OCCUPYING THE S1 POCKET</PDB_Title>
      <PDB_ID>2BVR</PDB_ID>
      <Resolution>1.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BVR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of Thrombin Inhibitor Fragments from Chemical Microarray Screening</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3</PDB_Title>
      <PDB_ID>1D3P</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1D3P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors.</PubMed_Title>
      <Author>Chirgadze, N.Y., et al.</Author>
      <Journal>Protein Sci.(2000)9:29-36</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10739244?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Thrombin in complex with inhibitor</PDB_Title>
      <PDB_ID>2GDE</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2GDE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Total synthesis and structural confirmation of chlorodysinosin A.</PubMed_Title>
      <Author>Hanessian, S., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2006)128:10491-10495</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16895415?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Specifity for Plasminogen Activator Inhibitor-1</PDB_Title>
      <PDB_ID>1VR1</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1VR1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop</PubMed_Title>
      <Author>Dekker, R.J., et al.</Author>
      <Journal>J.Mol.Biol.(1999)293:613-627</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10543954?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human alpha thrombin inhibited by RPPGF and hirugen</PDB_Title>
      <PDB_ID>1NY2</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NY2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin.</PubMed_Title>
      <Author>Hasan, A.A., et al.</Author>
      <Journal>Am.J.Physiol.Heart Circ.Physiol.(2003)285:H183-H193</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12598231?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE STRUCTURE OF A COMPLEX OF RECOMBINANT HIRUDIN AND HUMAN ALPHA-THROMBIN</PDB_Title>
      <PDB_ID>3HTC</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HTC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of a complex of recombinant hirudin and human alpha-thrombin.</PubMed_Title>
      <Author>Rydel, T.J., et al.</Author>
      <Journal>Science(1990)249:277-280</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/2374926?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON NMR MODEL OF DNA)</PDB_Title>
      <PDB_ID>1HAO</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HAO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>An ambiguous structure of a DNA 15-mer thrombin complex.</PubMed_Title>
      <Author>Padmanabhan, K., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(1996)52:272-282</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15299700?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>2.5A Crystal Structure of the Antithrombin-Thrombin-Heparin Ternary Complex</PDB_Title>
      <PDB_ID>1TB6</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TB6</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04220055;ASD04220056;ASD04220057;ASD04220058;ASD04220059;ASD04220060</ASD_Ligand>
      <PubMed_Title>Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin.</PubMed_Title>
      <Author>Li, W., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2004)11:857-862</Journal>
      <PubMed_ID>15311269</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of thrombin in complex with compound 1</PDB_Title>
      <PDB_ID>1TA2</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TA2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of a series of potent and orally bioavailable   noncovalent thrombin  inhibitors that utilize nonbasic groups in the P1 position</PubMed_Title>
      <Author>Tucker, T.J., et al.</Author>
      <Journal>J.Med.Chem.(1998)41:3210-3219</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9703466?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEX STRUCTURE</PDB_Title>
      <PDB_ID>1SR5</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SR5</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04220054</ASD_Ligand>
      <PubMed_Title>The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity.</PubMed_Title>
      <Author>Dementiev, A., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2004)11:863-867</Journal>
      <PubMed_ID>15311268</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Exploring thrombin S3 pocket</PDB_Title>
      <PDB_ID>2ZHW</PDB_ID>
      <Resolution>2.02</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZHW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exploring thrombin S3 pocket</PubMed_Title>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04610</Pathway_ID>
      <Pathway_Title>Complement and coagulation cascades</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04080</Pathway_ID>
      <Pathway_Title>Neuroactive ligand-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04810</Pathway_ID>
      <Pathway_Title>Regulation of actin cytoskeleton</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell motility</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.ia.b.c.bg.html</SCOP_URL>
    <CATH_Class>Class 2: Mainly Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1a2c</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Type>Open-Close</Site_Type>
    </AllostericSite>
  </AllostericSite_List>
  <Allosteric_Pathway>
    <Method>Crystallization, structural analysis, mutations.</Method>
    <Verified__Residue>D102, W215</Verified__Residue>
    <PubMed_Title>Gandhi PS, et al. Proc Natl Acad Sci U S A. 2008,105(6):1832-1837.</PubMed_Title>
    <PubMed_ID>18250335</PubMed_ID>
    <is__ref__img>Yes</is__ref__img>
    <is__display>No</is__display>
    <in__pathway__browse>Yes</in__pathway__browse>
  </Allosteric_Pathway>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>3.4.21.5</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/4/21/5.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00170297</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03160008</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04490012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04490014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04490016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872017</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872018</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872020</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872021</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872023</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872025</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872027</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872028</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872029</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872030</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872031</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872032</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872033</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872034</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872035</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872036</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872037</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872038</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872039</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872040</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872041</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872042</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872043</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872044</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872045</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872046</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872047</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872048</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05872049</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>